<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2105</journal-id><journal-id journal-id-type="pmc-domain">cancers</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11171065</article-id><article-id pub-id-type="pmcid-ver">PMC11171065.1</article-id><article-id pub-id-type="pmcaid">11171065</article-id><article-id pub-id-type="pmcaiid">11171065</article-id><article-id pub-id-type="pmid">38893120</article-id><article-id pub-id-type="doi">10.3390/cancers16111995</article-id><article-id pub-id-type="publisher-id">cancers-16-01995</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9884-1232</contrib-id><name name-style="western"><surname>Nikolouzakis</surname><given-names initials="TK">Taxiarchis Konstantinos</given-names></name><xref rid="af1-cancers-16-01995" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chrysos</surname><given-names initials="E">Emmanuel</given-names></name><xref rid="af1-cancers-16-01995" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8162-5955</contrib-id><name name-style="western"><surname>Docea</surname><given-names initials="AO">Anca Oana</given-names></name><xref rid="af2-cancers-16-01995" ref-type="aff">2</xref><xref rid="c1-cancers-16-01995" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fragkiadaki</surname><given-names initials="P">Persefoni</given-names></name><xref rid="af3-cancers-16-01995" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1642-1147</contrib-id><name name-style="western"><surname>Souglakos</surname><given-names initials="J">John</given-names></name><xref rid="af4-cancers-16-01995" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9892-1048</contrib-id><name name-style="western"><surname>Tsiaoussis</surname><given-names initials="J">John</given-names></name><xref rid="af5-cancers-16-01995" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3824-2462</contrib-id><name name-style="western"><surname>Tsatsakis</surname><given-names initials="A">Aristidis</given-names></name><xref rid="af3-cancers-16-01995" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Gobert</surname><given-names initials="AP">Alain P.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-cancers-16-01995"><label>1</label>Department of General Surgery, University General Hospital of Heraklion, 71110 Heraklion, Greece; <email>konstan10@hotmail.gr</email> (T.K.N.); <email>chrysose@uoc.gr</email> (E.C.)</aff><aff id="af2-cancers-16-01995"><label>2</label>Department of Toxicology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania</aff><aff id="af3-cancers-16-01995"><label>3</label>Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece; <email>persefoni_fragkiadaki@imbb.forth.gr</email> (P.F.); <email>tsatsaka@uoc.gr</email> (A.T.)</aff><aff id="af4-cancers-16-01995"><label>4</label>Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece; <email>souglak@uoc.gr</email></aff><aff id="af5-cancers-16-01995"><label>5</label>Department of Anatomy, Medical School, University of Crete, 70013 Heraklion, Greece; <email>tsiaoussis@uoc.gr</email></aff><author-notes><corresp id="c1-cancers-16-01995"><label>*</label>Correspondence: <email>ancadocea@gmail.com</email> or <email>anca.docea@umfcv.ro</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2024</year></pub-date><volume>16</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">464598</issue-id><elocation-id>1995</elocation-id><history><date date-type="received"><day>12</day><month>4</month><year>2024</year></date><date date-type="rev-recd"><day>15</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-19 19:25:14.043"><day>19</day><month>06</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cancers-16-01995.pdf"/><abstract><sec><title>Simple Summary</title><p>Colorectal cancer (CRC) has become one of the leading causes of cancer-related morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT) have been recently added to the clinical armamentarium of stage II/III diseases. Moreover, the improvement of a patient&#8217;s telomere status may have a synergistic effect along with ICIs/ACT. This can be achieved either via lifestyle modifications with increased physical activity or with new promising treatments such as those acting on telomerase. Therefore, this review aims to comprehensively summarize the current data on immunotherapy in order to facilitate clinicians&#8217; familiarity with this relatively new therapeutic approach.</p></sec><sec><title>Abstract</title><p>Cancer of the colon and rectum (CRC) has been identified among the three most prevalent types of cancer and cancer-related deaths for both sexes. Even though significant progress in surgical and chemotherapeutic techniques has markedly improved disease-free and overall survival rates in contrast to those three decades ago, recent years have seen a stagnation in these improvements. This underscores the need for new therapies aiming to augment patient outcomes. A number of emerging strategies, such as immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT), have exhibited promising outcomes not only in preclinical but also in clinical settings. Additionally, a thorough appreciation of the underlying biology has expanded the scope of research into potential therapeutic interventions. For instance, the pivotal role of altered telomere length in early CRC carcinogenesis, leading to chromosomal instability and telomere dysfunction, presents a promising avenue for future treatments. Thus, this review explores the advancements in CRC immunotherapy and telomere-targeted therapies, examining potential synergies and how these novel treatment modalities intersect to potentially enhance each other&#8217;s efficacy, paving the way for promising future therapeutic advancements.</p></sec></abstract><kwd-group><kwd>colorectal cancer</kwd><kwd>immunotherapy</kwd><kwd>telomeres</kwd><kwd>therapy</kwd><kwd>checkpoint inhibitors</kwd><kwd>adoptive cell therapy</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-16-01995"><title>1. Introduction</title><p>Recent evidence from global cancer registries places cancer of the colon and rectum (CRC) in the third place of the most common types of cancer, accounting for around 10% of all cases. Furthermore, CRC is identified as the second most common cause of cancer-related death worldwide [<xref rid="B1-cancers-16-01995" ref-type="bibr">1</xref>]. In fact, the International Agency for Research on Cancer estimated that in 2020, more than 1.9 million new patients and 900,000 deaths of CRC occurred worldwide [<xref rid="B2-cancers-16-01995" ref-type="bibr">2</xref>]. In the United States alone, projections for 2023 indicated approximately 153,020 new CRC diagnoses and 52,550 deaths attributed to the disease [<xref rid="B3-cancers-16-01995" ref-type="bibr">3</xref>]. Despite a decline in the age-adjusted death rate for CRC between 1990 and 2020, the pace of this decline has decelerated over the past decade [<xref rid="B4-cancers-16-01995" ref-type="bibr">4</xref>]. Besides epidemiological factors like global population growth, aging demographics, and the rising incidence of early-onset disease, the waning effectiveness of conventional therapeutic methods (including surgery, chemotherapy, and radiotherapy) is a significant contributing factor to this trend. Recent years have seen a surge in research focused on the comprehensive treatment of CRC, with combination therapy involving targeted agents emerging as the primary treatment approach for metastatic CRC (mCRC) patients [<xref rid="B5-cancers-16-01995" ref-type="bibr">5</xref>,<xref rid="B6-cancers-16-01995" ref-type="bibr">6</xref>]. However, despite ongoing advancements in medication regimens, making breakthroughs in mCRC therapy remains challenging, with prognoses still being bleak. This underscores the imperative for novel therapeutic modalities capable of either circumventing the primary cell-related mechanisms of chemotherapeutic drug resistance or enhancing the organism&#8217;s anti-tumor properties. A promising candidate that seems able to achieve, at least to some extent, this task is the immune system. In fact, solid tumors such asnon-small cell lung cancer (NSCLC) and melanoma have retrieved significant therapeutic results from immunotherapy [<xref rid="B7-cancers-16-01995" ref-type="bibr">7</xref>,<xref rid="B8-cancers-16-01995" ref-type="bibr">8</xref>]. Immune checkpoint inhibitors (ICIs) have allowed for persistent results in certain patients, leading to favorable results. Programmed Death-Ligand 1 (PD-L1) monoclonal antibodies used against Programmed Death 1 (PD-1) or Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) dramatically augmented the therapeutic armamentarium while also providing significant positive re-appreciation of prognosis across several solid tumors [<xref rid="B9-cancers-16-01995" ref-type="bibr">9</xref>,<xref rid="B10-cancers-16-01995" ref-type="bibr">10</xref>,<xref rid="B11-cancers-16-01995" ref-type="bibr">11</xref>]. However, owing to the increased variability of the underlying immunophenotypes, it is well appreciated that the clinical benefit from this pioneering therapeutic approach can vary for different cancer types [<xref rid="B12-cancers-16-01995" ref-type="bibr">12</xref>]. Current clinical data dictate that a portion of CRC patients with tumors where deficient mismatch repair or high microsatellite instability (dMMR/MSI-H) is identified, can benefit from the use of ICIs. This group is estimated to be around 15% of all CRC patients and 5% of those with metastatic CRC (mCRC) [<xref rid="B13-cancers-16-01995" ref-type="bibr">13</xref>,<xref rid="B14-cancers-16-01995" ref-type="bibr">14</xref>]. However, despite the high rate of durable responses, a fraction of them will develop immune resistance that can outweigh prolonged survival outcomes (approximately 15&#8211;29%) [<xref rid="B12-cancers-16-01995" ref-type="bibr">12</xref>,<xref rid="B15-cancers-16-01995" ref-type="bibr">15</xref>,<xref rid="B16-cancers-16-01995" ref-type="bibr">16</xref>]. Therefore, it is reasonable to speculate that ICIs&#8217; efficacy is closely related with the identification of quality tumor-specific lymphocytes in high numbers. Interestingly, adoptive cell therapy (ACT) has demonstrated promising results in cases with these characteristics [<xref rid="B17-cancers-16-01995" ref-type="bibr">17</xref>]. ACT is a sophisticated and, more importantly, individualized anti-cancer treatment, in which blood samples are retrieved from a patient, allowing for immune cell isolation, in vitro culture and modification, and thereafter re-administration back into the patient in order to selectively tackle the cancer. Through this process, cultured cells are able to specifically identify cancer cells and induce immune responses to eliminate them [<xref rid="B18-cancers-16-01995" ref-type="bibr">18</xref>]. In contrast to ICIs that greatly exert their action through antagonism of suppressor T-cell receptors, ACT providesits anticarcinogenic effect through isolating the expansion of a great volume of T cells that may overcome certain suppressive immunomodulatory parameters [<xref rid="B19-cancers-16-01995" ref-type="bibr">19</xref>]. Current research in CRC epigenetics highlights the important role of telomeres and their regulating enzyme, telomerase, not only as clinical biomarkers but also as potential therapeutic targets [<xref rid="B20-cancers-16-01995" ref-type="bibr">20</xref>,<xref rid="B21-cancers-16-01995" ref-type="bibr">21</xref>,<xref rid="B22-cancers-16-01995" ref-type="bibr">22</xref>,<xref rid="B23-cancers-16-01995" ref-type="bibr">23</xref>,<xref rid="B24-cancers-16-01995" ref-type="bibr">24</xref>,<xref rid="B25-cancers-16-01995" ref-type="bibr">25</xref>,<xref rid="B26-cancers-16-01995" ref-type="bibr">26</xref>,<xref rid="B27-cancers-16-01995" ref-type="bibr">27</xref>]. However, it is also well established that immune responses may be negatively affected in cases of telomere attrition [<xref rid="B27-cancers-16-01995" ref-type="bibr">27</xref>,<xref rid="B28-cancers-16-01995" ref-type="bibr">28</xref>]. This is important because it is proven that in CRC patients, peripheral blood lymphocytes (PBLs) contain shorter telomeres than those of healthy individuals [<xref rid="B29-cancers-16-01995" ref-type="bibr">29</xref>] while telomerase is also down-regulated [<xref rid="B27-cancers-16-01995" ref-type="bibr">27</xref>]. This observation implies that improving telomere length (TL) and increasing telomerase activity (TA) may augment the efficacy of immune-mediated therapies such as ACT and ICIs [<xref rid="B30-cancers-16-01995" ref-type="bibr">30</xref>]. In <xref rid="cancers-16-01995-t001" ref-type="table">Table 1</xref>, a summary of the different therapeutic approaches in immunotherapy for CRC is presented.</p></sec><sec id="sec2-cancers-16-01995"><title>2. Genetic Determinants of Immune Response</title><sec id="sec2dot1-cancers-16-01995"><title>2.1. Mismatch Repair Complex and Microsatellite Status in CRC</title><p>Microsatellites (MSs) are short repeated sequences of 1&#8211;6 nucleotides located in both coding and non-coding regions scattered throughout the genome. It is observed that MSs are susceptible to duplication errors through strand slippage during DNA synthesis [<xref rid="B31-cancers-16-01995" ref-type="bibr">31</xref>]. Despite this, the mismatch repair (MMR) system is responsible for correcting these errors [<xref rid="B32-cancers-16-01995" ref-type="bibr">32</xref>,<xref rid="B33-cancers-16-01995" ref-type="bibr">33</xref>]. However, a defective MMR system (dMMR) can lead to DNA mistakes and subsequent microsatellite instability (MSI). MSI is identified as an alteration of microsatellite length caused by the insertion or deletion of a repetitive unit, allowing for new microsatellite alleles to be formed [<xref rid="B34-cancers-16-01995" ref-type="bibr">34</xref>]. Therefore, the presence of MSI indicates dMMR and hypermutability of cells [<xref rid="B35-cancers-16-01995" ref-type="bibr">35</xref>]. According to the mutant number of microsatellite sites, MMR defects can arise from somatic mutations, epigenetic silencing (such as hypermethylation of the hMLH1 promoter in sporadic cases), or germline genetic alterations (as seen in Lynch syndrome), resulting in MSI due to point mutations in MMR genes like hMSH2, hMSH6, hMLH1, PMS2, and PMS1 [<xref rid="B36-cancers-16-01995" ref-type="bibr">36</xref>]. The first steps of a MS profile can be evaluated using the Bethesda gene status, which includes 5 MS loci (D5S346, BAT26, D17S250, BAT25, and D2S123) [<xref rid="B37-cancers-16-01995" ref-type="bibr">37</xref>]; however, a number of researchers have proposed an extended version of this with 10 loci. Based on this panel, MSI is categorized into three groups: MSI-low (MSI-L), where 10&#8211;30% of the loci are unstable; MSI-high (MSI-H), which exhibits &#8805;30% unstable loci; and microsatellite stable (MSS), with &lt;10% unstable loci [<xref rid="B38-cancers-16-01995" ref-type="bibr">38</xref>]. An MSI-H/dMMR phenotype is identified in roughly 15&#8211;18% of stage II CRCs, and in stage III and IV disease settings, it accounts for approximately 10% and 5% of cases, respectively [<xref rid="B39-cancers-16-01995" ref-type="bibr">39</xref>]. However, the prognostic significance of MSI/dMMR in such stages is debated [<xref rid="B40-cancers-16-01995" ref-type="bibr">40</xref>]. CRC exhibiting a dMMR/MSI-H profile tends to be located in the right colon, while a constellation of unfavorable characteristics such as distant lymph node metastases, peritoneal cavity spread, mucus secretion, and poor differentiation accompanies it [<xref rid="B41-cancers-16-01995" ref-type="bibr">41</xref>,<xref rid="B42-cancers-16-01995" ref-type="bibr">42</xref>]. Nonetheless, it has been proved that this phenotype also has increased immunogenic properties inducing high immune cell infiltration, particularly from tumor-infiltrating lymphocytes [<xref rid="B12-cancers-16-01995" ref-type="bibr">12</xref>,<xref rid="B43-cancers-16-01995" ref-type="bibr">43</xref>]. Therefore, this molecular subset&#8217;s immune sensitivity is attributed to the high mutational burden from MMR deficiency, resulting in an augmented presentation of immunogenic neoantigens and a rich tumor microenvironment infiltrated by immune cells [<xref rid="B12-cancers-16-01995" ref-type="bibr">12</xref>]. In contrast, tumors with a proficient MMR (pMMR) or MSS phenotype exhibit low immunogenicity [<xref rid="B44-cancers-16-01995" ref-type="bibr">44</xref>], leading to decreased expression of checkpoint proteins and low or no T-cell tumor infiltration, explaining their intrinsic resistance to ICIs. In order to overcome this resistance, a therapeutic armamentarium consisting of ICIs and anti-cancer agents with immunomodulatory effects (e.g., anti-VEGFR or anti-EGFR) has been proposed to enhance the immunogenic profile of these lesions and make checkpoint blockade more effective [<xref rid="B45-cancers-16-01995" ref-type="bibr">45</xref>,<xref rid="B46-cancers-16-01995" ref-type="bibr">46</xref>].</p></sec><sec id="sec2dot2-cancers-16-01995"><title>2.2. BRAFV600E</title><p>BRAF is a serine-threonine protein kinase positioned downstream in the KRAS signaling cascade. Assessing BRAFV600E mutations holds crucial significance for both effective genetic/oncologic counseling and prognostication. The coexistence of the BRAFV600E mutation with deficient mismatch repair (dMMR) strongly suggests a sporadic tumor, obviating the need for oncogenetic referral [<xref rid="B47-cancers-16-01995" ref-type="bibr">47</xref>]. Additionally, identifying this mutation indicates a poorer outcome in both stage II and III CRC cases [<xref rid="B48-cancers-16-01995" ref-type="bibr">48</xref>] Specifically, the presence of the BRAFV600E mutation predicts an unfavorable prognosis in right-sided microsatellite stable (MSS) CRC and undervalued effects of systemic treatment regardless of the use of targeted therapy [<xref rid="B49-cancers-16-01995" ref-type="bibr">49</xref>]. The BRAFV600E mutation is frequently linked with the hypermethylator phenotype (CpG island methylator phenotype), which is able to induce MSI-H status via hypermethylation of the MLH1 gene promoter [<xref rid="B50-cancers-16-01995" ref-type="bibr">50</xref>]. Recent research of four mCRC studies revealed that 21% of BRAFV600E(+) cases were also MSI-H/dMMR, while 35% of MSI-H/dMMR cases were BRAFV600E(+) [<xref rid="B40-cancers-16-01995" ref-type="bibr">40</xref>]. Despite growing evidence indicating that dMMR/BRAFV600E(&#8722;) tumors exhibit improved overall survival (OS) compared to dMMR/BRAFV600E(+) and proficient MMR (pMMR)/BRAFV600E(&#8722;) or pMMR/BRAFV600E(+) tumors [<xref rid="B49-cancers-16-01995" ref-type="bibr">49</xref>,<xref rid="B51-cancers-16-01995" ref-type="bibr">51</xref>], the presence of the BRAFV600E mutation does not predict outcomes for patients who have MSI-H mCRC that is managed with ICIs. Furthermore, the KEYNOTE-177 phase III study showed pembrolizumab&#8217;s increased efficiency over first-line systemic treatment with or without additional targeted therapy, irrespective of BRAF mutational status [<xref rid="B52-cancers-16-01995" ref-type="bibr">52</xref>]. Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [<xref rid="B53-cancers-16-01995" ref-type="bibr">53</xref>,<xref rid="B54-cancers-16-01995" ref-type="bibr">54</xref>,<xref rid="B55-cancers-16-01995" ref-type="bibr">55</xref>,<xref rid="B56-cancers-16-01995" ref-type="bibr">56</xref>].</p></sec></sec><sec id="sec3-cancers-16-01995"><title>3. Immune Response in CRC</title><p>One of the primary mechanisms by which an organism identifies and eliminates cells that may have evaded cell-cycle regulation and become neoplastic is through its immune system. Tumor cells can activate a host&#8217;s immune system via a complex pathway encompassing not only the adaptive immune system (T and B lymphocytes) but also the innate system (such as mast cells, dendritic cells (DCs), macrophages, natural killer (NK) cells, neutrophils, and myeloid-derived suppressor cells) [<xref rid="B57-cancers-16-01995" ref-type="bibr">57</xref>]. For an immune cell to recognize a neoplastic cell, the latter must express modified molecules on its surface, typically proteins resulting from DNA mutations or epigenetic alterations [<xref rid="B58-cancers-16-01995" ref-type="bibr">58</xref>,<xref rid="B59-cancers-16-01995" ref-type="bibr">59</xref>]. In a typical scenario, innate immune cells like NK cells identify the absence of MHC-I surface molecules on cancer cells, leading to the active elimination of cancer cells and subsequent recruitment of other inflammatory cells through cytokine production [<xref rid="B60-cancers-16-01995" ref-type="bibr">60</xref>]. Monocytes recruited to the site, particularly DCs and macrophages, destroy tumor cells and transport tumor-associated antigens on their surface, initiating a specific cytolytic T-cell response targeted against the tumor [<xref rid="B61-cancers-16-01995" ref-type="bibr">61</xref>]. This sequence of events is referred to as the cancer&#8211;immune cycle [<xref rid="B62-cancers-16-01995" ref-type="bibr">62</xref>]. A series of studies have shown that the identification of tumor-specific T cells is linked to favorable outcomes in various human cancers [<xref rid="B63-cancers-16-01995" ref-type="bibr">63</xref>]. Nonetheless, anti-tumor immunity is not always elucidated, as T cells can also lead to cancer progression [<xref rid="B64-cancers-16-01995" ref-type="bibr">64</xref>]. CD8+ T cells and CD4+ effector T cells have demonstrated anti-cancer potential, while regulatory T cells (CD4+ CD25+ Tregs) have been shown to be able to contribute to the attenuated immune response exhibited in cancer [<xref rid="B65-cancers-16-01995" ref-type="bibr">65</xref>,<xref rid="B66-cancers-16-01995" ref-type="bibr">66</xref>]. CD8+ T cells are regarded as one of the most promising T-cell subsets for an effective anti-tumor response [<xref rid="B65-cancers-16-01995" ref-type="bibr">65</xref>,<xref rid="B67-cancers-16-01995" ref-type="bibr">67</xref>]. In the case of dMMR/MSI-H CRCs, there is heightened immunogenicity, leading to a significantly increased number of tumor-infiltrating CD8+ T lymphocytes (TILs) and a good prognosis [<xref rid="B68-cancers-16-01995" ref-type="bibr">68</xref>,<xref rid="B69-cancers-16-01995" ref-type="bibr">69</xref>]. Several immune-triggering antigens, such as mutated Caspase-5, TGF&#946;IIR, or CDX2 have been identified in MSI-H CRCs [<xref rid="B70-cancers-16-01995" ref-type="bibr">70</xref>]. Moreover, MSI-H results in the upregulation of immune checkpoint proteins (like PD-1 and PD-L1), facilitating immune evasion via tumor-infiltrating lymphocytes, rather than tumor cells [<xref rid="B71-cancers-16-01995" ref-type="bibr">71</xref>]. Given the prognostic importance of TILs in the tumor microenvironment, special scores evaluating specific immunologic parameters (such as Immunoscore<sup>&#174;</sup>) have been developed [<xref rid="B72-cancers-16-01995" ref-type="bibr">72</xref>]. In CRC, the &#8220;hot&#8221; immune phenotype, characterized by significant T-cell infiltration, is often observed in tumors with MSI-H, likely owing to a high tumor mutational load and the presentation of neoantigens, fostering anti-cancer immunity (<xref rid="cancers-16-01995-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec4-cancers-16-01995"><title>4. Immune Evasion of CRC</title><p>Neoplastic cells must deactivate certain inhibitory mechanisms and establish new defensive strategies to ensure their survival and proliferation. Immune evasion stands out as a crucial mechanism among these strategies. Initially, immune cells work to eliminate all cancerous cells upon detection. However, some groups of tumor cells manage to surpass the immune system&#8217;s regulatory functions, achieving a balance between elimination and proliferation. Over time, a subset of cancer cells emerges that is able to evade the immune system&#8217;s suppressive effects, resulting in the creation of clinically significant cancers. This process is encapsulated by the &#8220;three Es of cancer immunoediting&#8221;: equilibrium, escape, and elimination [<xref rid="B73-cancers-16-01995" ref-type="bibr">73</xref>]. Neoplastic cells employ various tactics to achieve immune escape, including altering surface molecules (such as the depletion or down-regulation of HLA I antigens), activating suppressor T cells, manipulating death receptor signaling responses, secreting immunosuppressive cytokines, and inducing apoptosis of activated T cells [<xref rid="B67-cancers-16-01995" ref-type="bibr">67</xref>]. Cell surface molecules act by facilitating interactions between cells and their environment, mediating signaling pathways, and enabling cell attachment to the extracellular matrix (ECM). These molecules undergo dynamic modifications in response to intrinsic and extrinsic stimuli and vary between cell types and developmental stages. Notably, alterations in cell surface molecules contribute significantly to pathological conditions, including cancer and its metastasis [<xref rid="B74-cancers-16-01995" ref-type="bibr">74</xref>,<xref rid="B75-cancers-16-01995" ref-type="bibr">75</xref>]. The down-regulation of the HLA class I antigen in CRC, for instance, enables neoplastic cells to evade cytotoxic T cell lymphocyte (CTL) mediated lysis by bypassing the MHC-restricted, antigen-specific triggering of the T-cell receptor (TCR) complex [<xref rid="B76-cancers-16-01995" ref-type="bibr">76</xref>]. Additionally, evidence supports the involvement of Fas/Fas Ligand (FasL) interplay in immune evasion [<xref rid="B77-cancers-16-01995" ref-type="bibr">77</xref>], with neoplasms showing resistance to Fas-mediated cytotoxicity and FasL expression potentially resulting in immune effector cells apoptosis [<xref rid="B76-cancers-16-01995" ref-type="bibr">76</xref>,<xref rid="B78-cancers-16-01995" ref-type="bibr">78</xref>]. Furthermore, regulatory T cells (Treg), a subset of CD4+ T cells, accumulate in the tumor microenvironment, contributing to immune escape mechanisms [<xref rid="B79-cancers-16-01995" ref-type="bibr">79</xref>]. Cancer cells also directly inhibit the immune system through molecules like vascular endothelial growth factor (VEGF), prostaglandin E2, transforming growth factor-&#946; (TGF- &#946;), and interleukin-10 (IL-10), which suppress cytotoxic T-cell function [<xref rid="B77-cancers-16-01995" ref-type="bibr">77</xref>,<xref rid="B78-cancers-16-01995" ref-type="bibr">78</xref>,<xref rid="B80-cancers-16-01995" ref-type="bibr">80</xref>,<xref rid="B81-cancers-16-01995" ref-type="bibr">81</xref>,<xref rid="B82-cancers-16-01995" ref-type="bibr">82</xref>,<xref rid="B83-cancers-16-01995" ref-type="bibr">83</xref>]. This allows for the emergence of suppressed CD 4+ and CD 8+ T lymphocytes that are not identified as foreign antigens [<xref rid="B84-cancers-16-01995" ref-type="bibr">84</xref>]. Additionally, cancer cells can increase immune checkpoint molecules such as PD-L1, resulting in peripheral T cell exhaustion and the inhibition of malignant cell apoptosis [<xref rid="B85-cancers-16-01995" ref-type="bibr">85</xref>].</p></sec><sec id="sec5-cancers-16-01995"><title>5. Immune Checkpoints</title><sec id="sec5dot1-cancers-16-01995"><title>5.1. Programmed Death Ligand 1 (PD L1) and Programmed Death 1 (PD-1)</title><p>T cell receptors Cytotoxic T lymphocyte antigen 4 (CTLA-4) and Programmed Cell Death 1 (PD-1) have a synergistic inhibitory effect on the T cell immune response. Interestingly, tumor cells take advantage of this inhibitory effect in order to induce T-cell tolerance and exhaustion [<xref rid="B86-cancers-16-01995" ref-type="bibr">86</xref>]. A neoplasm&#8217;s microenvironment is where the PD-1/PD-L1 pathway closely controls the creation and long-term establishment of immune tolerance. It has been shown that PD-L1 or PD-L2, acting through their ligation to PD-1, may induce anti-cancer immune responses. This is achieved through the direct modulation of T-cell activity, proliferative capacity, and cytotoxicity in cancer, leading to deprived responses [<xref rid="B87-cancers-16-01995" ref-type="bibr">87</xref>]. PD-1, also known as CD279, was initially discovered in 2B4-11 (murine T-cell hybridoma) and interleukin-3 (IL-3)-deprived LyD9 (murine hematopoietic progenitor) cell lines in 1992 [<xref rid="B88-cancers-16-01995" ref-type="bibr">88</xref>]. Studies have demonstrated that PD-1 shares approximately 13%, 15%, and 20% similarity with induced T-cell co-stimulators CD28 and CTLA4, accordingly [<xref rid="B89-cancers-16-01995" ref-type="bibr">89</xref>]. Functionally, PD-1 is able to exert its inhibitory effects on both innate and adaptive immune responses and is able to activate macrophages, T cells, B lymphocytes, DCs, NK, and monocytes [<xref rid="B90-cancers-16-01995" ref-type="bibr">90</xref>]. The transcription of PD-1 is induced by various transcription factors, among which are NOTCH, interferon (IFN), regulatory factor 9 (IRF9), nuclear factor of activated T cells (NFAT), and Forkhead box protein (FOX) O1 [<xref rid="B91-cancers-16-01995" ref-type="bibr">91</xref>]. Two well-maintained upstream regulatory regions, B and C (CR-B and COR-C), have been identified as crucial for the expression of the PD-1 gene [<xref rid="B87-cancers-16-01995" ref-type="bibr">87</xref>]. Specifically, c-FOS connects to special areas in the CR-B region, enhancing PD-1 expression and stimulating T-cell receptors following antigen detection from naive T cells [<xref rid="B92-cancers-16-01995" ref-type="bibr">92</xref>]. However, it is well established that neoplastic cells exploit the regulatory action of the c-FOS subunit of Activator protein 1 (AP1) by increasing its expression, thereby upregulating PD-1 expression [<xref rid="B93-cancers-16-01995" ref-type="bibr">93</xref>]. Overall, PD-1 appears to play two opposing roles as an immune supervisor by restricting immune cells from prolonged ineffective or harmful responses, while on the other hand allowing for immune cells to develop tolerance. Another interesting way that PD-1 promotes survival and proliferation of cancer cells is via negative interference with the immune response [<xref rid="B94-cancers-16-01995" ref-type="bibr">94</xref>]. The PD-1 ligand (PD-L1), also known as CD279 and B7-H1, is a 33kDa type 1 transmembrane glycoprotein belonging to the B7 series. It has an extracellular region with two domains (Ig- and IgC) consisting of 290 amino acids [<xref rid="B95-cancers-16-01995" ref-type="bibr">95</xref>]. PD-L1 is typically found on the surface of dendritic cells (DCs), macrophages, and some activated T cells and B cells. In addition, if inflammation is present, PD-L1 can be expressed on certain epithelial cells [<xref rid="B96-cancers-16-01995" ref-type="bibr">96</xref>]. Remarkably, cancer cells have managed to develop a certain &#8220;adaptive immune mechanism&#8221; by expressing PD-L1 on their surface. If so, tumor cells can evade anti-cancer immune responses [<xref rid="B97-cancers-16-01995" ref-type="bibr">97</xref>]. A series of studies have demonstrated that PD-L1 can be upregulated by IFN-&#947; in various cancer models, primarily through the MEK/ERK and MYD88/TRAF6 pathways [<xref rid="B98-cancers-16-01995" ref-type="bibr">98</xref>]. Recent studies indicate that PD-L1 upregulation on tumor cells can be achieved via IFN-&#947; secretion from NK cells. This is possible because of the JAK1/JAK2 and STAT1 pathways, leading to tumor cell survival and disease progression [<xref rid="B99-cancers-16-01995" ref-type="bibr">99</xref>,<xref rid="B100-cancers-16-01995" ref-type="bibr">100</xref>]. Indeed, tumor proliferation and survival can be mediated through the connection of PD-L1 to its receptors [<xref rid="B101-cancers-16-01995" ref-type="bibr">101</xref>]. The PD-1/PD-L1 axis can interact with various pathways, including MAPK, PI3K/AKT, WNT, JAK/STAT, Hedgehog (Hh), and NF-&#954;B, ultimately contributing to tumor progression [<xref rid="B102-cancers-16-01995" ref-type="bibr">102</xref>,<xref rid="B103-cancers-16-01995" ref-type="bibr">103</xref>,<xref rid="B104-cancers-16-01995" ref-type="bibr">104</xref>,<xref rid="B105-cancers-16-01995" ref-type="bibr">105</xref>,<xref rid="B106-cancers-16-01995" ref-type="bibr">106</xref>,<xref rid="B107-cancers-16-01995" ref-type="bibr">107</xref>,<xref rid="B108-cancers-16-01995" ref-type="bibr">108</xref>]. Overall, PD-L1 expression has been linked to poor clinical outcomes, being more common in mCRC [<xref rid="B109-cancers-16-01995" ref-type="bibr">109</xref>]. Interestingly, current data suggest that cancers with MSI-H exhibit upregulation of immune checkpoint proteins like PD-1 and PD-L1, facilitating immune evasion through tumor-infiltrating lymphocytes rather than tumor cells themselves [<xref rid="B71-cancers-16-01995" ref-type="bibr">71</xref>]. Nevertheless, the expression of PD-L1 in mCRC is not associated with an immunotherapy response [<xref rid="B110-cancers-16-01995" ref-type="bibr">110</xref>].</p></sec><sec id="sec5dot2-cancers-16-01995"><title>5.2. Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4)</title><p>Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a pivotal inhibitory receptor that modulates T-cell function and plays a crucial role in the initial phase of immune responses [<xref rid="B111-cancers-16-01995" ref-type="bibr">111</xref>]. Also known as CD152, CTLA-4 is a 25 kDa molecule consisting of a leader peptide, a ligand binding domain, a transmembrane domain, and a cytoplasmic domain. In humans, three isoforms are produced through gene splicing: full-length CTLA-4, soluble CTLA-4, and forms involving exon 1 and exon 4 [<xref rid="B112-cancers-16-01995" ref-type="bibr">112</xref>]. CTLA-4 exerts its inhibitory effects by influencing T-cell function, particularly during the priming phase of immune responses [<xref rid="B113-cancers-16-01995" ref-type="bibr">113</xref>]. Its expression is upregulated in response to stronger stimulatory signals through the T-cell receptor (TCR), leading to translocation to the T cell surface [<xref rid="B114-cancers-16-01995" ref-type="bibr">114</xref>]. On the T-cell membrane, CTLA-4 exhibits higher binding avidity to B7 molecules compared to CD28, thus competing with CD28 to regulate costimulation and induce anergy [<xref rid="B115-cancers-16-01995" ref-type="bibr">115</xref>]. Additionally, CTLA-4 is constitutively expressed on regulatory T cells (Tregs) to maintain their suppressive functions and inhibit other T cells by interacting with B7 molecules [<xref rid="B116-cancers-16-01995" ref-type="bibr">116</xref>]. The downstream signaling of CTLA-4 involves the induction of NF-&#954;B, AP-1, and clustering of zeta chain-associated protein kinase 70 (ZAP-70), which are key molecules in TCR signaling pathways [<xref rid="B117-cancers-16-01995" ref-type="bibr">117</xref>]. Furthermore, the CTLA-4/CD80, CD86 axis established between immune cells and tumor cells has been implicated in attenuating anti-tumoral immune responses in the tumor microenvironment [<xref rid="B118-cancers-16-01995" ref-type="bibr">118</xref>]. Blocking CTLA-4 with antibodies increases CD8+ lymphocytes and depletes Tregs. However, depletion of Tregs alone does not enhance anti-tumor responses; rather, a combination of enhanced effector T cell function and the inhibition of Treg activity is necessary for maximal anti-tumor activity [<xref rid="B119-cancers-16-01995" ref-type="bibr">119</xref>]. Anti- CTLA-4antibodies have been shown to deplete intratumoral Tregs, possibly through antibody-dependent cell-mediated cytotoxicity, leading to enhanced anti-tumor responses [<xref rid="B120-cancers-16-01995" ref-type="bibr">120</xref>]. Additionally, studies by Allison et al. using murine colon carcinoma and fibrosarcoma models demonstrated that co-administration of anti-CTLA-4 antibodies with tumor lysate-loaded dendritic cells can reduce Tregs, increase CD8+ lymphocytes, inhibit metastatic growth, and prolong survival [<xref rid="B121-cancers-16-01995" ref-type="bibr">121</xref>].</p></sec></sec><sec id="sec6-cancers-16-01995"><title>6. Immune Checkpoint Inhibitors (ICIs)</title><p>ICIs such as anti-CTLA-4, anti-PD-1, and anti-PD-L1 can bind to these co-inhibitory receptors, effectively reviving the anti-cancer immune response [<xref rid="B122-cancers-16-01995" ref-type="bibr">122</xref>]. The US Food and Drug Administration (FDA) has approved three distinct categories of ICIs for treating various cancer types: CTLA-4 inhibitors (Ipilimumab), PD-L1 inhibitors (such as Atezolimumab, Avelumab, and Durvalumab), and PD-1 inhibitors (including Pembrolizumab, Nivolumab, and Cemiplimab).</p><sec id="sec6dot1-cancers-16-01995"><title>6.1. Anti-PD1/PDL-1 Abs</title><p>Monoclonal antibodies targeting PD-1/PD-L1 interactions have been demonstrated to enhance T cell activity against cancer cells by restoring their activation, proliferation, function, and downstream immune signaling [<xref rid="B123-cancers-16-01995" ref-type="bibr">123</xref>]. Among the FDA-approved PD-1 inhibitors, three are specifically approved for CRC treatment. Nivolumab, an anti-PD1 monoclonal antibody (moAb), has been utilized since 1 August 2017, for MSI-H/dMMR mCRC, as evidenced by the CheckMate 142 study [<xref rid="B54-cancers-16-01995" ref-type="bibr">54</xref>]. Pembrolizumab, another anti-PD1 moAb, received approval on 29 June 2020, as a first-line treatment for patients with unresectable or metastatic MSI-H/dMMR CRC based on the KEYNOTE-177 study [<xref rid="B124-cancers-16-01995" ref-type="bibr">124</xref>]. Atezolizumab, an anti-PDL1 moAb, has been investigated for previously treated mCRC with or without cobimetinib, compared to regorafenib. However, it did not achieve its primary endpoint of improved OS [<xref rid="B125-cancers-16-01995" ref-type="bibr">125</xref>]. Nevertheless, a phase 2 study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05118724">NCT05118724</ext-link>) is currently ongoing, assessing the efficacy of atezolizumab with or without IMM-101 in patients with MSI-H/dMMR stage III CRC ineligible for oxaliplatin [<xref rid="B126-cancers-16-01995" ref-type="bibr">126</xref>]. Dostarlimab, a humanized anti-PD-1 moAb, is utilized in patients with locally advanced rectal cancer that is dMMR [<xref rid="B127-cancers-16-01995" ref-type="bibr">127</xref>].</p></sec><sec id="sec6dot2-cancers-16-01995"><title>6.2. Anti-CTLA-4 Abs</title><p>Two human monoclonal antibodies targeting CTLA-4 have been developed for patient use: MDX-010, also known as ipilimumab and marketed as Yervoy, and CP-675, also known as tremelimumab [<xref rid="B128-cancers-16-01995" ref-type="bibr">128</xref>,<xref rid="B129-cancers-16-01995" ref-type="bibr">129</xref>]. It has been shown that in a clinical setting, the use of these inhibiting anti-CTLA-4 antibodies is able to enhance the activity of effector T cells while suppressing regulatory T cells, resulting in net inhibition of tumor progression [<xref rid="B130-cancers-16-01995" ref-type="bibr">130</xref>]. Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [<xref rid="B54-cancers-16-01995" ref-type="bibr">54</xref>,<xref rid="B131-cancers-16-01995" ref-type="bibr">131</xref>]. <xref rid="cancers-16-01995-f002" ref-type="fig">Figure 2</xref> provides an illustration of the PD1/CTLA-4 T-cell pathways.</p></sec></sec><sec id="sec7-cancers-16-01995"><title>7. Adoptive Cell Therapy (ACT)</title><p>ACT is a highly personalized cancer treatment approach wherein immune cells are extracted from tumor patients, expanded and modified in laboratory settings, and subsequently reintroduced into the patient&#8217;s body. This process enables the modified cells to specifically target tumor cells, triggering autologous immune responses to eradicate them [<xref rid="B18-cancers-16-01995" ref-type="bibr">18</xref>]. However, the application of ACT in solid tumors encounters significant limitations and challenges, primarily stemming from the availability and quality of isolated immune cells. Firstly, the process involves identifying and isolating specific tumor antigens to train the immune cells effectively. These cells must survive in vitro before being reintroduced into the patient [<xref rid="B132-cancers-16-01995" ref-type="bibr">132</xref>]. Secondly, while ACT demonstrates high efficacy, it also comes with notable toxicity risks, particularly concerning cytokine release syndrome (CRS). Lastly, there are challenges associated with delivering tumor-specific lymphocytes efficiently to the tumor site [<xref rid="B133-cancers-16-01995" ref-type="bibr">133</xref>].</p><sec id="sec7dot1-cancers-16-01995"><title>7.1. Chimeric Antigen Receptor (CAR) T-Cell Therapy</title><p>CAR T-cells are genetically modified to produce a synthetic T-cell receptor designed to target surface antigens located on cancer cells. These receptors, known as chimeric antigen receptors (CARs), are modified proteins consisting of four parts: an extracellular antigen-binding domain, a hinge region, a transmembrane (TM) domain, and an intracellular signaling domain [<xref rid="B134-cancers-16-01995" ref-type="bibr">134</xref>]. The extracellular domain is able to recognize and bind to tumor antigens. A single-chain fragment variable (scFv) is its main component that is created from the light and heavy chain variable region (VL and VH accordingly) of antibodies. Between the extracellular domain (antigen-binding) and the TM domain is the hinge region (also known as the spacer region). This is created from a combination of IgG4 and CD8. CARs are connected to the cell membrane via the TM domain and the hinge region. The intracellular signaling domain (that comprises CD3&#950; and various synergistic proteins) has the potential to propagate immune responses that are specific to antigens and directly influence the effectiveness of CARs in activating T cells [<xref rid="B135-cancers-16-01995" ref-type="bibr">135</xref>]. Typically, current variants of chimeric receptors contain a single-chain variable fragment portion of the target receptor, coupled with the costimulatory intracellular domain of 4-1BB, CD28 or OX40 [<xref rid="B136-cancers-16-01995" ref-type="bibr">136</xref>]. While CAR T-cell therapy has demonstrated promising efficacy in B-cell hematologic malignancies [<xref rid="B137-cancers-16-01995" ref-type="bibr">137</xref>], its success in treating solid tumors is less robust, possibly due to the limited availability of targetable antigens or inefficient trafficking of CAR T cells to tumor sites [<xref rid="B130-cancers-16-01995" ref-type="bibr">130</xref>]. Nevertheless, the clinician needs to bear in mind that despite the great effectiveness of CAR T-cell therapy, there is a considerable risk of toxicity, particularly the hazard of developing cytokine release syndrome (CRS) [<xref rid="B138-cancers-16-01995" ref-type="bibr">138</xref>]. This risk underscores the importance of the careful selection of target antigens, as they play a crucial role in determining the effectiveness and safety profile of CAR T-cell therapy. Given that the majority of solid tumors are of epithelial origin, the identification of tumor-specific antigens (TSAs) is unusual [<xref rid="B139-cancers-16-01995" ref-type="bibr">139</xref>]. Unfortunately, given that the antigen targets used for anti-CRC CAR T-cell therapy are often expressed in normal cells, the accurate recognition of tumor-associated antigens (TAAs) is rather difficult, resulting in a therapy with low specificity [<xref rid="B140-cancers-16-01995" ref-type="bibr">140</xref>].</p></sec><sec id="sec7dot2-cancers-16-01995"><title>7.2. Tumor-Infiltrating Lymphocyte (TIL) Therapy</title><p>Tumor-infiltrating lymphocytes (TILs) are isolated from samples retrieved from tissue biopsies or surgical specimens and are located close to the tumor. Following isolation, cells are proliferated in vitro using interleukin-2 (IL-2) and then are introduced back into patients in order to produce a robust immune-mediated anti-tumor response [<xref rid="B141-cancers-16-01995" ref-type="bibr">141</xref>]. Successful TIL therapy relies on the presence of preexisting tumor-reactive lymphocytes in patients, which can be expanded ex vivo. However, identifying these specific lymphocytes, especially in patients with tumors other than melanoma, can be challenging [<xref rid="B141-cancers-16-01995" ref-type="bibr">141</xref>]. For gastrointestinal tumors, such as CRC, the primary hurdle in developing TIL therapy may not lie in the in vitro expansion of bulk TILs but rather in the ability to select and enrich tumor-reactive T cells [<xref rid="B142-cancers-16-01995" ref-type="bibr">142</xref>]. Despite these challenges, TIL therapy has shown promising results. For instance, in the case of metastatic CRC (mCRC), multiple lung metastatic lesions exhibited objective regression after the infusion of HLA-C*08:02-restricted TILs targeting KRAS G12D specifically [<xref rid="B143-cancers-16-01995" ref-type="bibr">143</xref>]. As of January 2024, there are 14 clinical trials underway to assess the feasibility and safety of TIL cells for CRC treatment. Detailed information about these trials can be found on the ClinicalTrials.gov website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03935893">NCT03935893</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04426669">NCT04426669</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03610490">NCT03610490</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02980146">NCT02980146</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01174121">NCT01174121</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05573035">NCT05573035</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05902520">NCT05902520</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05610592">NCT05610592</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04622423">NCT04622423</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05524012">NCT05524012</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03960021">NCT03960021</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03904537">NCT03904537</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00019084">NCT00019084</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05576077">NCT05576077</ext-link>).</p></sec></sec><sec id="sec8-cancers-16-01995"><title>8. Anti-Tumor Vaccine Therapy</title><p>The idea behind cancer vaccination originates from acknowledging that the immune system possesses inherent modules to identify modified self-antigens found on many cancer cells, commonly referred to as tumor-associated antigens [<xref rid="B144-cancers-16-01995" ref-type="bibr">144</xref>]. As for the vaccines created for infectious diseases, the primary objective of anti-cancer vaccines is to promote an immune response aiming to eradicate tumors and establish continuous monitoring to prevent their recurrence. Up until now, Up until now, four main platforms of anti-tumor vaccines have been studied: those utilizing dendritic cells (DCs), peptide antigens, viral or bacterial vectors and those utilizing ehole tumor antigens [<xref rid="B145-cancers-16-01995" ref-type="bibr">145</xref>]. A summary of the main immune-mediated anti-tumor vaccines is presented in <xref rid="cancers-16-01995-t002" ref-type="table">Table 2</xref>.</p><p>Whole tumor vaccines: This was the first type of anti-tumor vaccine that was tested. For the majority of cases, the method involved the use of a sample of neoplastic tissue, which was submitted either to lysis or irradiation. Subsequently, it was combined with an immune adjuvant, such as alum, before being reintroduced to the donor (patient) [<xref rid="B146-cancers-16-01995" ref-type="bibr">146</xref>]. In fact, the idea of autologous whole tumors being used as a vaccine platform has been utilized in various types of immunogenic cancers like CRC [<xref rid="B147-cancers-16-01995" ref-type="bibr">147</xref>], renal cell carcinoma [<xref rid="B148-cancers-16-01995" ref-type="bibr">148</xref>], and melanoma [<xref rid="B149-cancers-16-01995" ref-type="bibr">149</xref>]. Unfortunately, despite the initial enthusiasm for whole tumor vaccines, current evidence suggests limited efficacy. For instance, in CRC, a phase III randomized clinical trial was conducted, where patients with stage II and III CRC were administered autologous whole cancer cells that were combined with a BCG vaccine. This trial aimed to assess whether surgical resection coupled with vaccination was superior to resection. However, the study failed to demonstrate a significant benefit in terms of OS or disease-free survival (DFS). Nonetheless, it was observed that both improved DFS and OS were achieved given the potent immune response [<xref rid="B147-cancers-16-01995" ref-type="bibr">147</xref>]. An inherent challenge with whole tumor vaccines lies in the fact that only a small fraction of the proteins within an autologous whole tumor vaccine are exclusive to malignant cells. The majority of antigens contained in the vaccine are common with normal cells, which diminishes the concentration of tumor-specific antigens while potentially triggering an autoimmune response. Additionally, whole tumor vaccines tend to exhibit poor immunogenicity. Consequently, the immune response elicited by these vaccines is often inadequate to confer significant benefits to patients, as demonstrated by the average outcomes observed in previous studies [<xref rid="B150-cancers-16-01995" ref-type="bibr">150</xref>].</p><p>Peptide antigen vaccines: Given that cancer cells express a great amount of common proteins with normal cells, this restricts immune cells from targeting them, making whole tumor vaccines less effective. On the contrary, peptide vaccines are suggested to provoke an immune reaction against a particular identified tumor antigen. These vaccines consist of entire proteins or protein fragments derived from tumor-specific proteins, administered alongside an adjuvant [<xref rid="B151-cancers-16-01995" ref-type="bibr">151</xref>]. The main drawback is the human leukocyte antigen (HLA)-type restricted nature of the therapy. This is because HLA molecules are expressed in a variety of super-types and only a particular HLA-super-type can recognize a specific antigen. In the clinical setting, this means that only those patients who carry the required HLA allele will be able to respond to the therapy, which substantially limits its application [<xref rid="B152-cancers-16-01995" ref-type="bibr">152</xref>]. In the case of CRC, numerous tumor-associated antigens have been identified and utilized in order to target MHC class I. Among these antigens are carcinoembryonic antigen (CEA), mucin-1, squamous cell carcinoma antigen recognized by T cells 3 (SART3), &#946;-human chorionic gonadotropin (&#946;-hCG), Survivin-2B, and p53 [<xref rid="B153-cancers-16-01995" ref-type="bibr">153</xref>,<xref rid="B154-cancers-16-01995" ref-type="bibr">154</xref>]. However, clinical trials have shown mixed results even though the overall trend was positive [<xref rid="B155-cancers-16-01995" ref-type="bibr">155</xref>,<xref rid="B156-cancers-16-01995" ref-type="bibr">156</xref>].</p><p>Viral vector vaccines: Due to the relatively low stimulating capacity of peptide antigen vaccines, several teams have tried to augment the generated immune response via the use of viral or bacterial vectors. In fact, a recombinant virus engineered to express tumor-associated antigens utilizes the inherent immunogenicity of viruses, as they tend to naturally infect antigen-presenting cells, particularly dendritic cells (DCs). Taking it a step forward, the co-introduction of tumor antigens along with co-stimulatory molecules in a viral vector seems to be an even more effective way to trigger an effective immune response [<xref rid="B157-cancers-16-01995" ref-type="bibr">157</xref>]. Such an example is the CEA/TRICOM vaccine which utilizes CEA as the target protein and combines this with three co-stimulatory molecules (TRICOM) B7.1 (CD80), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3) all packed within a viral vector [<xref rid="B158-cancers-16-01995" ref-type="bibr">158</xref>]. Interestingly this type of vaccine has given some promising results as evidenced in a murine model of colon cancer [<xref rid="B159-cancers-16-01995" ref-type="bibr">159</xref>].</p><p>Dendritic cells vaccines: While the effectiveness of previous categories relies upon the stimulation of the immune system in order to elucidate an anti-tumor immune response, the final category utilizes autologous DCs in order to orchestrate the anti-tumor response. This can be achieved because DCs have the potential to activate T cells through antigen presentation by MHC. One way to achieve this is via the generation of ex vivo DCs capable of activating anti-tumor CTLs through the isolation of CD14+ monocytes from peripheral blood. Following this, the next step is to differentiate and manipulate them into antigen-presenting mature monocyte-derived DCs (moDCs) which are then delivered back to the patient [<xref rid="B160-cancers-16-01995" ref-type="bibr">160</xref>]. Despite the promising responses observed, a significant portion of patients have not experienced clinical benefits. It could be argued that moDCs may have an inherently suboptimal ability to provoke T-cell responses [<xref rid="B161-cancers-16-01995" ref-type="bibr">161</xref>]. Unfortunately, ex vivo DC differentiation and manipulation is time-consuming and expensive, while also available in very few laboratories [<xref rid="B70-cancers-16-01995" ref-type="bibr">70</xref>].</p></sec><sec id="sec9-cancers-16-01995"><title>9. Emerging Biomarkers of Clinical Response</title><p>In current clinical practice, various biomarkers such as PD-L1 expression, tumor mutational burden (TMB), MSI, microbiome composition, hypoxia levels, IFN-&#947; levels, and extracellular matrix characteristics are utilized as prognostic indicators to predict the clinical response to immunotherapy among patients receiving ICIs [<xref rid="B162-cancers-16-01995" ref-type="bibr">162</xref>]. Recent findings suggest that assessing the densities of T and B cells within CRC tumors offers higher accuracy compared to evaluating PD-L1 expression alone in predicting the efficacy of immunotherapy. This is because PD-L1 expression can vary heterogeneously within different regions of a tumor, while metastatic CRC lesions may exhibit varying immunoscores [<xref rid="B163-cancers-16-01995" ref-type="bibr">163</xref>,<xref rid="B164-cancers-16-01995" ref-type="bibr">164</xref>]. Despite significant advancements in identifying biomarkers for ICIs, Fuc&#224; et al. conducted a study evaluating the impact of metastatic site location on clinical response. Their findings revealed that the presence of peritoneal metastases and ascites correlated with poorer outcomes in a cohort of 502 patients with dMMR/MSI-H mCRC treated with ICIs. This association has been attributed to the presence of an immune-suppressive environment within serous cavities, potentially hindering the efficacy of immunotherapy [<xref rid="B165-cancers-16-01995" ref-type="bibr">165</xref>]. POLE and POLD1 enzymes play pivotal roles in DNA replication, crucial for synthesizing and repairing DNA. The exonuclease domain (ED) of POLE and POLD1 has the ability to repair replicating errors of the DNA. Therefore, mutations located in the DNA binding or catalytic site of the ED of POLE or POLD1 can lead to proofreading defects. Consequently, increased TMB is closely related to an absent or impaired DNA repair system that results in an ultra-mutated phenotype of tumor cells. For this reason, the abundance of mutation-associated neoantigens identified in tumors with mutations in POLE or POLD1 makes them heavily immunogenic. This, in turn, allows them to be potentially sensitive to immune checkpoint inhibition [<xref rid="B166-cancers-16-01995" ref-type="bibr">166</xref>]. Previous work on this topic has shown that pMMR/MSS tumors baring POLE- or POLD1-mutations are often diagnosed at earlier stages and exhibit favorable prognoses compared to cases with wild-type POLE or POLD1 [<xref rid="B167-cancers-16-01995" ref-type="bibr">167</xref>]. POLE-mutated tumors are characterized by certain elements such as infiltration of CD8+ T cells at higher rates, greater expression of cytotoxic markers, and upregulation of immune checkpoints in contrast to POLE wild-type pMMR/MSS tumors. Additionally, they demonstrate a similar enrichment of CD8+ T cells as observed in tumors with dMMR/MSI-H phenotypes, suggesting a similar underlying biology between these two subgroups of CRC tumors [<xref rid="B167-cancers-16-01995" ref-type="bibr">167</xref>].</p></sec><sec id="sec10-cancers-16-01995"><title>10. Dynamics of Telomere Length</title><p>Chromosomal ends consist of special DNA structures named telomeres. These are created by the repetition of certain nucleotide sequences (5&#8242;-TTAGGG-3&#8242;) [<xref rid="B168-cancers-16-01995" ref-type="bibr">168</xref>]. These sequences are non-coding, but along with other proteins (shelterins), protect from chromosomal damage, instability, and degradation [<xref rid="B168-cancers-16-01995" ref-type="bibr">168</xref>]. Shelterin is a complex of proteins comprising six subunits&#8212;TRF1, TRF2, TIN2, TPP1, and POT1 [<xref rid="B169-cancers-16-01995" ref-type="bibr">169</xref>]. Together, shelterins and telomeres create T-loops, keeping DNA repair mechanisms from identifying telomeres as double-stranded DNA breaks. However, during each mitotic cell division, DNA polymerases are unable to fully replicate the lagging strand of telomere DNA at the chromosome end, resulting in an annual telomere shortening rate of approximately 20&#8211;40 base pairs [<xref rid="B170-cancers-16-01995" ref-type="bibr">170</xref>,<xref rid="B171-cancers-16-01995" ref-type="bibr">171</xref>]. Additional factors (processing of telomeres during the cell cycle, reactive oxygen species) also worsen telomere shortening [<xref rid="B172-cancers-16-01995" ref-type="bibr">172</xref>]. Combined, these events initiate a DNA damage response that creates two key situations: (1) introduces irreversible cell cycle arrest, and (2) initiates cellular senescence that is characterized by changes in chromatin, gene expression, organelles, and cell morphology [<xref rid="B173-cancers-16-01995" ref-type="bibr">173</xref>]. Nevertheless, despite the theory of telomere attrition seeming logical, it is not able to explain senescence in non-proliferating, quiescent, or terminally differentiated cells, suggesting a more complicated pathway [<xref rid="B174-cancers-16-01995" ref-type="bibr">174</xref>]. Telomerase, an enzyme with reverse-transcriptase action, can counteract this loss of telomeric length by synthesizing telomeric DNA elements using an RNA template [<xref rid="B175-cancers-16-01995" ref-type="bibr">175</xref>]. Telomerase comprises a number of proteins such as telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC), along with various proteins essential for DNA synthesis. Despite this, TERC is ubiquitously expressed in various human cells, and TERT is suppressed in order to prevent uncontrolled cell replication [<xref rid="B176-cancers-16-01995" ref-type="bibr">176</xref>]. In addition, it is well established that due to its suppression, TERT acts as a rate-limiter of telomerase activity [<xref rid="B177-cancers-16-01995" ref-type="bibr">177</xref>]. This is important because if TERT is upregulated, then TA will be increased, allowing cells to overcome replicative senescence. Doing so, telomeres become dysfunctional, which allows for continuous &#8220;breakage-fusion-bridge&#8221; cycles, chromosomal fusions, gene amplifications, derived chromosome imbalances, and the formation of complex non-reciprocal translocations to take place, a hallmark feature of adult solid tumors and genomic instability in general [<xref rid="B178-cancers-16-01995" ref-type="bibr">178</xref>]. However, neoplastic cells may also achieve genomic instability through short telomeres. In fact, it is believed that at the early stages of neoplastic transformation, telomere shortening reaches a critical length, at which senescence would be triggered. However, oncogenic changes help the cell to bypass senescence and continue divisions until multiple critically shortened telomeres initiate crisis (a period of complete replicative senescence, chromosome end-to-end fusions, and extensive apoptosis). If the neoplastic cell has acquired certain oncogenic modifications, it will overcome the crisis and continue to replicate. Eventually, in many cases, hTERT will be upregulated and TA will be increased, leading to longer TL [<xref rid="B179-cancers-16-01995" ref-type="bibr">179</xref>]. This fulfills one of the ten hallmarks of carcinogenesis (as described by the Hanahan&#8211;Weinberg model for successful oncogenesis [<xref rid="B180-cancers-16-01995" ref-type="bibr">180</xref>]), which is the initiation of replicative immortality. In mutated cells, TERT is upregulated owing to the carcinogenic properties of transcription factors Myc, nuclear factor kappa B (NF-kB), and b catenin [<xref rid="B181-cancers-16-01995" ref-type="bibr">181</xref>]. It has to be noted though that apart from initiating replicative immortality, telomerase seems to play a crucial role in almost all the hallmarks of cancer, ranging from cell growth and proliferation through to the activation of EGFR signaling [<xref rid="B182-cancers-16-01995" ref-type="bibr">182</xref>], resistance to apoptosis through activation of NF-kB [<xref rid="B183-cancers-16-01995" ref-type="bibr">183</xref>], and the promotion of invasion and metastasis through induction of the epithelial&#8211;mesenchymal transition via the Wnt/b-catenin pathway that upregulates Snail-1 and vimentin [<xref rid="B184-cancers-16-01995" ref-type="bibr">184</xref>], up to direct and indirect (through Myc) modification of energy metabolism [<xref rid="B185-cancers-16-01995" ref-type="bibr">185</xref>]. It has been shown that homeostasis of the telomeric ends can be regulated by protein parts of the shelterin complex [<xref rid="B186-cancers-16-01995" ref-type="bibr">186</xref>,<xref rid="B187-cancers-16-01995" ref-type="bibr">187</xref>]. Two different key regulators of TA are the actual structure of telomeres and the cell cycle-dependent creation of active telomerase. Both of them seem to restrict TA at chromosome ends during the S phase of each cell cycle [<xref rid="B188-cancers-16-01995" ref-type="bibr">188</xref>]. However, it is rather interesting that during each cell cycle, TA seems to be concentrated primarily to these telomeric ends whose length reaches a critically short length (telomeric prioritization) [<xref rid="B22-cancers-16-01995" ref-type="bibr">22</xref>,<xref rid="B189-cancers-16-01995" ref-type="bibr">189</xref>]. The level of TA and the corresponding TL are the two major elements affecting telomere homeostasis. Throughout the cell cycle, telomeres fluctuate between different states (stationary/nonextendible, elongetable, and elongating) [<xref rid="B188-cancers-16-01995" ref-type="bibr">188</xref>]. Moreover, recent data indicate that telomeres in mammals have the ability of transcription into telomeric repeat-containing RNA (TERRA) molecules, representing a novel type of mammalian RNAs. This comes in contrast to the notion that telomeres are non-coding regions of the DNA [<xref rid="B190-cancers-16-01995" ref-type="bibr">190</xref>]. In fact, telomere transcription seems to be mediated from within the telomere region of CpG islands with promoter activity (identified within subtelomeric regions). These promoters have been found to be able to initiate transcription of TERRAs, containing UUAGGG repeats [<xref rid="B191-cancers-16-01995" ref-type="bibr">191</xref>]. Despite a lack of universal consensus regarding the main function of TERRAs, this seems to be the formation of telomeric heterochromatin, the protection of telomeres, and the negative regulation of telomerase [<xref rid="B192-cancers-16-01995" ref-type="bibr">192</xref>].</p></sec><sec id="sec11-cancers-16-01995"><title>11. Telomere Length and CRC</title><p>Cancer cells can overcome cell cycle arrest and activate telomerase, allowing them to proliferate and acquire mutations. In cancer research, significant attention has been given to understanding the regulation of the human telomerase reverse transcriptase (hTERT), which plays a crucial role in cancer. Various mechanisms have been identified to alter hTERT gene expression, including methylation of its promoter, mutational changes within the promoter, amplifications, and structural variations [<xref rid="B193-cancers-16-01995" ref-type="bibr">193</xref>]. Recent studies on CRC have revealed that TL from malignant cells tends to be shorter than in neighboring &#8220;healthy&#8221; mucosa [<xref rid="B194-cancers-16-01995" ref-type="bibr">194</xref>]. Additionally, the clinical stage of the malignancy seems to be correlated with TL. In fact, cancers at lower stages tend to have shorter telomeres in contrast to advanced and metastatic cancers [<xref rid="B194-cancers-16-01995" ref-type="bibr">194</xref>]. The correlation between TL and cancer has been widely demonstrated, with more than 6000 peer-reviewed scientific and clinical publications in this specific field. In a recent study, Nikolouzakis et al. showed that TL in PBLs from patients with mCRC tends to decrease with age (especially for patients over 75 years old) when compared to healthy individuals of the same age, while chemotherapy seemed to also have a negative impact on the mean TL of mCRC patients [<xref rid="B29-cancers-16-01995" ref-type="bibr">29</xref>]. In this study, metaphase Q-FISH technology was used for the determination of TL in PBL samples. This technique is the most accurate and precise compared to others since it measures each telomere end in each chromosome in each cell, avoiding the false measurement of the interstitial telomere regions of the chromosomes, and allows the recognition of telomere-free ends which lead to chromosomal instability and are linked with age-related diseases such as colon CRC [<xref rid="B195-cancers-16-01995" ref-type="bibr">195</xref>,<xref rid="B196-cancers-16-01995" ref-type="bibr">196</xref>]. Some researchers, such as Luu et al. [<xref rid="B197-cancers-16-01995" ref-type="bibr">197</xref>] and Peacock et al. [<xref rid="B198-cancers-16-01995" ref-type="bibr">198</xref>], have reported that the risk of developing CRC seems to be higher in people with longer telomeres. An explanation they provide dictates that there is an increased risk of mutational accumulation with carcinogenic potential as a result of longer telomeres. Nevertheless, this theory seems to be wrong, as a meta-analysis failed to identify any significant association between TL and the risk for CRC development [<xref rid="B199-cancers-16-01995" ref-type="bibr">199</xref>]. Regarding TL and tumor location, while earlier findings suggested that rectal cancers had a tendency to bear longer telomeres [<xref rid="B200-cancers-16-01995" ref-type="bibr">200</xref>], a formal correlation between TL and tumor location is still debated. Furthermore, TL has emerged as a potential predictive biomarker for the clinical outcome of anti-EGFR monoclonal antibody therapy in patients with KRAS wild-type metastatic CRC. Therefore, investigations are underway to determine whether mutations in the KRAS oncogene impact telomere deregulation [<xref rid="B21-cancers-16-01995" ref-type="bibr">21</xref>,<xref rid="B24-cancers-16-01995" ref-type="bibr">24</xref>,<xref rid="B27-cancers-16-01995" ref-type="bibr">27</xref>,<xref rid="B29-cancers-16-01995" ref-type="bibr">29</xref>,<xref rid="B133-cancers-16-01995" ref-type="bibr">133</xref>].</p></sec><sec id="sec12-cancers-16-01995"><title>12. Telomerase Activity and CRC</title><p>TA in CRC has been detected in a significant percentage of tumor samples, ranging from 80% to 100% [<xref rid="B201-cancers-16-01995" ref-type="bibr">201</xref>], highlighting its role as a pivotal step in CRC carcinogenesis [<xref rid="B202-cancers-16-01995" ref-type="bibr">202</xref>]. In contrast, TA has been found in normal mucosa samples at a lower frequency, ranging from 9% to 53% [<xref rid="B22-cancers-16-01995" ref-type="bibr">22</xref>,<xref rid="B203-cancers-16-01995" ref-type="bibr">203</xref>]. Across numerous studies, neoplastic mucosa consistently exhibited higher TA compared to corresponding healthy mucosa. However, Nikolouzakis et al., studying TA in PBLs from 28 patients with mCRC, described that TA presented a significant trend of increase (<italic toggle="yes">p</italic> = 0.07) in patients with progressive disease at the middle of their treatment when compared with that before the initiation [<xref rid="B27-cancers-16-01995" ref-type="bibr">27</xref>]. Researchers have identified TA as an independent prognostic factor for DFS, recurrence, and OS in CRC patients, with high levels of TERT and/or TA typically associated with poorer prognosis [<xref rid="B204-cancers-16-01995" ref-type="bibr">204</xref>]. Studying TA indirectly can be achieved by assessing hTERT expression, as its acquisition appears essential for TA in most human tumors [<xref rid="B205-cancers-16-01995" ref-type="bibr">205</xref>]. There is a strong correlation between hTERT expression and TA, and recent studies have linked hTERT promoter hypermethylation to CRC and other cancer types [<xref rid="B206-cancers-16-01995" ref-type="bibr">206</xref>]. Additionally, elevated levels of hTERT have been linked to OS in CRC patients [<xref rid="B207-cancers-16-01995" ref-type="bibr">207</xref>]. In fact, the identification of hTERT transcripts in the plasma of CRC patients may serve as a useful tool for disease monitoring, as mRNA levels correlate with those found in tumors [<xref rid="B208-cancers-16-01995" ref-type="bibr">208</xref>]. The prognostic and predictive significance of cell-free circulating hTERT has been evaluated in CRC patients in detail [<xref rid="B207-cancers-16-01995" ref-type="bibr">207</xref>,<xref rid="B209-cancers-16-01995" ref-type="bibr">209</xref>,<xref rid="B210-cancers-16-01995" ref-type="bibr">210</xref>]. Bertorelle et al. showed that stage II CRC patients with lower levels of hTERT had better OS, while its presence at higher levels was correlated with a poor response to chemotherapy (as an independent prognostic factor) and with a higher risk of disease recurrence and death [<xref rid="B207-cancers-16-01995" ref-type="bibr">207</xref>]. However, owing to the fact that the extracellular compartment contains RNases, the estimation of circulating hTERT transcripts is unreliable due to mRNA digestion [<xref rid="B211-cancers-16-01995" ref-type="bibr">211</xref>]. For this purpose, exosomes containing hTERT can be evaluated. Exosomes are small (30&#8211;150 nm) particles arising from the endosomal membrane compartment. They contain miRNA, mRNA, proteins, DNA, and lipids. It has been shown that a variety of both normal and neoplastic cells can secrete them (among which are CRC cells) into the microenvironment from where they enter the bloodstream. Exosomes offer the advantage that their mRNA content is not exposed to the activity of extracellular RNases, allowing for reliable estimation [<xref rid="B210-cancers-16-01995" ref-type="bibr">210</xref>]. In summary, ample evidence supports telomerase as a useful marker for monitoring and predicting outcomes in CRC [<xref rid="B207-cancers-16-01995" ref-type="bibr">207</xref>].</p></sec><sec id="sec13-cancers-16-01995"><title>13. Therapeutic Implications of Telomerase Activity Inhibition</title><p>Anti-telomerase cancer therapy aims to inhibit or suppress TA in cancer cells through various inhibitors targeting different pathways. Currently, the primary telomerase inhibitor in clinical trials is GRN163L, an antisense oligodeoxynucleotide that complements the template region of human telomerase RNA (hTR) [<xref rid="B212-cancers-16-01995" ref-type="bibr">212</xref>]. By blocking telomerase&#8217;s catalytic activity, GRN163L induces progressive telomere shortening, leading to senescence and apoptosis. Preclinical studies in vitro and in vivo have paved the way for phase II human clinical trials [<xref rid="B212-cancers-16-01995" ref-type="bibr">212</xref>,<xref rid="B213-cancers-16-01995" ref-type="bibr">213</xref>]. Cancer immunotherapy offers another avenue for anti-telomerase inhibition by targeting telomerase-positive malignant cells. hTERT serves as a tumor-associated antigen, generating peptides that, when presented with class I major histocompatibility molecules, can stimulate cytotoxic T-lymphocytes to attack cancer cells. Several phase I and II clinical trials utilizing TERT-directed vaccines have shown promising results [<xref rid="B213-cancers-16-01995" ref-type="bibr">213</xref>,<xref rid="B214-cancers-16-01995" ref-type="bibr">214</xref>]. The EGFR pathway plays a crucial role in regulating the telomerase complex [<xref rid="B215-cancers-16-01995" ref-type="bibr">215</xref>]. Antisense oligonucleotides targeting EGFR have demonstrated significant inhibition of TA, along with TL reduction in various cell lines [<xref rid="B216-cancers-16-01995" ref-type="bibr">216</xref>]. Studies have revealed the coexistence of EGFR expression and TA in human uterine cervix epithelial cells [<xref rid="B217-cancers-16-01995" ref-type="bibr">217</xref>]. Additionally, downstream targets of EGFR signaling, such as the hypoxia-inducible factor 1-alpha (HIF1-&#945;) and the PI3K/AKT pathway, contribute to the transcriptional regulation of hTERT, further linking EGFR activation to telomerase regulation [<xref rid="B218-cancers-16-01995" ref-type="bibr">218</xref>]. TL has emerged as a potential predictive biomarker of clinical outcome, particularly progression-free survival (PFS), in response to anti-EGFR therapy in patients with KRas wild-type mCRC [<xref rid="B219-cancers-16-01995" ref-type="bibr">219</xref>]. Augustine et al. demonstrated in vitro that shorter TL correlated with restricted growth in response to cetuximab (an anti-EGFR antibody), while patients with longer TL exhibited a longer PFS when treated with EGFR inhibitors (cetuximab/panitumumab) [<xref rid="B220-cancers-16-01995" ref-type="bibr">220</xref>]. Integrating TL into biomarker screening alongside Ras mutations could refine patient selection for anti-EGFR therapy, optimizing treatment efficacy [<xref rid="B219-cancers-16-01995" ref-type="bibr">219</xref>]. The extensive literature linking the EGFR pathway with the TL/telomerase complex underscores the potential utility of TL as a predictive marker in anti-EGFR therapy [<xref rid="B218-cancers-16-01995" ref-type="bibr">218</xref>].</p></sec><sec id="sec14-cancers-16-01995"><title>14. Potential Interplay between Telomere Length and Immune Therapies</title><p>Various environmental drivers or chronic diseases have the potential to accelerate the physiological aging process related to telomeres in leukocytes [<xref rid="B221-cancers-16-01995" ref-type="bibr">221</xref>]. Furthermore, maintaining a consistently healthy lifestyle has been proposed as a strategy to alleviate the impact of hazardous effects on TL [<xref rid="B171-cancers-16-01995" ref-type="bibr">171</xref>,<xref rid="B222-cancers-16-01995" ref-type="bibr">222</xref>]. Additionally, the proinflammatory milieu of tumors and their microenvironment may add to the overall negative impact of telomere shortening. Evidence suggests that telomere shortening can be triggered by age-independent immune senescence that is caused by tumor-associated inflammation [<xref rid="B223-cancers-16-01995" ref-type="bibr">223</xref>]. It is well established that mature cells of myeloid lineage do not undergo division as compared to mature lymphocytes. Therefore, it is expected that the TL measured in leukocytes reflects cumulative or average lengths over cells with potentially diverse replications. Moreover, TL naive T cells are longer than that of memory T cells [<xref rid="B224-cancers-16-01995" ref-type="bibr">224</xref>]. The same stands for CD28+ T cells as compared to more differentiated lines such as CD28&#8722; or CD8+ T cells [<xref rid="B225-cancers-16-01995" ref-type="bibr">225</xref>,<xref rid="B226-cancers-16-01995" ref-type="bibr">226</xref>]. Cross-sectional analyses demonstrate progressive shortening of TL IN with advancing age in leukocytes or peripheral blood mononuclear cells (PBMCs), as well as in isolated granulocytes and lymphocytes (CD4 and CD8 T cells, and B cells) [<xref rid="B227-cancers-16-01995" ref-type="bibr">227</xref>]. According to the above observations, it can be stated that telomere attrition in blood leukocytes of both lineages (myeloid and lymphoid) is a fact, with TL being dependent upon age and differentiation. Some individuals exhibit a suboptimal response to vaccines, possibly due to various factors. Dysfunctional telomeres may contribute to this phenomenon. As observed in chronic viral infections, repetitive stimulation leads to extensive proliferation and the shortening of telomeres in antigen-specific T cells, ultimately leading to exhaustion [<xref rid="B228-cancers-16-01995" ref-type="bibr">228</xref>]. According to Rolles et al., patients with a longer TL had better OS as compared to those with shorter telomeres, regardless of the type of cancer. Moreover, it has to be noted that TL had no effect on patients&#8217; response to ICI therapy. The authors assumed that the observed difference in OS can be explained by the fact that shorter telomeres may be associated with increased non-tumor-related mortality.</p></sec><sec sec-type="conclusions" id="sec15-cancers-16-01995"><title>15. Conclusions</title><p>As the diagnosis of CRC increasingly affects a younger population and the prevalence of advanced stages of the disease rises, the imperative to expand CRC treatment modalities becomes ever more pressing. Substantial progress has been achieved in elucidating the immune system&#8217;s pivotal role in cancer pathogenesis, including CRC. This analysis has revealed two noteworthy trends that are presently shaping and will persistently influence cancer therapy in the foreseeable future: the employment of immune cell markers for predicting cancer outcomes and the targeting of diverse aspects of the immune system to induce an anti-tumor immune response. Immunotherapy for CRC has mainly been integrated as an adjuvant therapy alongside established first-line approaches, primarily directed at patients with dMMR/MSI-H and/or mCRC. Numerous investigations are ongoing to broaden the applicability of CRC immunotherapy, exploring additional biomarkers or microenvironments that modulate the anti-tumor immune response and evaluating immunotherapy, particularly ICIs, as both a primary and standalone mode of CRC treatment. Simultaneously, TL and TA have already demonstrated their clinical relevance as prognostic and/or predictive biomarkers of response in CRC therapy, while therapeutic strategies targeting hTERT are also under scrutiny. However, TL and TA also serve as crucial indicators of immune status. Consequently, interventions aimed at enhancing TL/TA hold promise as adjunctive approaches to enhance the response to anti-cancer immune therapy.</p><p>
<list list-type="simple"><list-item><p>Pearls:</p></list-item></list>
<list list-type="simple"><list-item><label>(1)</label><p>In cases of early-stage CRC, the dMMR/MSI-H profile is more common (10&#8211;18%) than that of mCRC (about 3&#8211;5%).</p></list-item><list-item><label>(2)</label><p>Activation and inhibitory signals of T cells are mediated through CTLA-4 [<xref rid="B229-cancers-16-01995" ref-type="bibr">229</xref>].</p></list-item><list-item><label>(3)</label><p>A suppression of immune responses is exhibited by the interplay of PD-1 and PD-L1/PD-L2, inducing a minimized function of T effector cells over immune responses.</p></list-item><list-item><label>(4)</label><p>PD-L1 is highly expressed in inflamed cells and PD-L2 is expressed only in antigen-presenting cells [<xref rid="B230-cancers-16-01995" ref-type="bibr">230</xref>].</p></list-item></list>
</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>T.K.N. and A.T., conceptualization; T.K.N. and E.C., methodology; T.K.N., P.F. and A.O.D., investigation; T.K.N. and P.F., writing&#8212;original draft preparation; E.C., J.S. and J.T., writing&#8212;review and editing; A.T., supervision. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-cancers-16-01995"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedrick</surname><given-names>T.L.</given-names></name></person-group><article-title>Colorectal Cancer</article-title><source>Surg. Oncol. Clin. N. Am.</source><year>2022</year><volume>31</volume><fpage>xv</fpage><lpage>xvi</lpage><pub-id pub-id-type="doi">10.1016/j.soc.2022.02.001</pub-id><pub-id pub-id-type="pmid">35351282</pub-id></element-citation></ref><ref id="B2-cancers-16-01995"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="B3-cancers-16-01995"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Wagle</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Cercek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Colorectal cancer statistics, 2023</article-title><source>CA Cancer J. Clin.</source><year>2023</year><volume>73</volume><fpage>233</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.3322/caac.21772</pub-id><pub-id pub-id-type="pmid">36856579</pub-id></element-citation></ref><ref id="B4-cancers-16-01995"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.B.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.Y.</given-names></name></person-group><article-title>A systematic analysis of the global and regional burden of colon and rectum cancer and the difference between early- and late-onset CRC from 1990 to 2019</article-title><source>Front. Oncol.</source><year>2023</year><volume>13</volume><fpage>1102673</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1102673</pub-id><pub-id pub-id-type="pmid">36874104</pub-id><pub-id pub-id-type="pmcid">PMC9975717</pub-id></element-citation></ref><ref id="B5-cancers-16-01995"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benson</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Venook</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Al-Hawary</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Azad</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Ciombor</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garrido-Laguna</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Rectal Cancer, Version 2.2022</article-title><source>JNCCN J. Natl. Compr. Cancer Netw.</source><year>2022</year><volume>20</volume><fpage>1139</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2022.0051</pub-id><pub-id pub-id-type="pmid">36240850</pub-id></element-citation></ref><ref id="B6-cancers-16-01995"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolouzakis</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Stivaktakis</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Apalaki</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalliantasi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sapsakos</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Spandidos</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Tsatsakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Souglakos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tsiaoussis</surname><given-names>J.</given-names></name></person-group><article-title>Effect of systemic treatment on the micronuclei frequency in the peripheral blood of patients with metastatic colorectal cancer</article-title><source>Oncol. Lett.</source><year>2019</year><volume>17</volume><fpage>2703</fpage><lpage>2712</lpage><pub-id pub-id-type="doi">10.3892/ol.2019.9895</pub-id><pub-id pub-id-type="pmid">30854044</pub-id><pub-id pub-id-type="pmcid">PMC6365930</pub-id></element-citation></ref><ref id="B7-cancers-16-01995"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bondarenko</surname><given-names>I.</given-names></name><name name-style="western"><surname>O&#8217;Day</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garbe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lebbe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baurain</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Testori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grob</surname><given-names>J.-J.</given-names></name><etal/></person-group><article-title>Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>364</volume><fpage>2517</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1104621</pub-id><pub-id pub-id-type="pmid">21639810</pub-id></element-citation></ref><ref id="B8-cancers-16-01995"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brahmer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reckamp</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Baas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crin&#242;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eberhardt</surname><given-names>W.E.E.</given-names></name><name name-style="western"><surname>Poddubskaya</surname><given-names>E.</given-names></name><name name-style="western"><surname>Antonia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pluzanski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vokes</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Holgado</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Nivolumab versus Docetaxel in Advanced Squamous-Cell Non&#8211;Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>123</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1504627</pub-id><pub-id pub-id-type="pmid">26028407</pub-id><pub-id pub-id-type="pmcid">PMC4681400</pub-id></element-citation></ref><ref id="B9-cancers-16-01995"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>O&#8217;Day</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hassel</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Improved Survival with Ipilimumab in Patients with Metastatic Melanoma</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1003466</pub-id><pub-id pub-id-type="pmid">20525992</pub-id><pub-id pub-id-type="pmcid">PMC3549297</pub-id></element-citation></ref><ref id="B10-cancers-16-01995"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Abreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cs&#337;szi</surname><given-names>T.</given-names></name><name name-style="western"><surname>F&#252;l&#246;p</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gottfried</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peled</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tafreshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cuffe</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Pembrolizumab versus Chemotherapy for PD-L1&#8211;Positive Non&#8211;Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>1823</fpage><lpage>1833</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1606774</pub-id><pub-id pub-id-type="pmid">27718847</pub-id></element-citation></ref><ref id="B11-cancers-16-01995"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rittmeyer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barlesi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Waterkamp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ciardiello</surname><given-names>F.</given-names></name><name name-style="western"><surname>von Pawel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Dols</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>255</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32517-X</pub-id><pub-id pub-id-type="pmid">27979383</pub-id><pub-id pub-id-type="pmcid">PMC6886121</pub-id></element-citation></ref><ref id="B12-cancers-16-01995"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borelli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Antoniotti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carullo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Germani</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Conca</surname><given-names>V.</given-names></name><name name-style="western"><surname>Masi</surname><given-names>G.</given-names></name></person-group><article-title>Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>4974</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14204974</pub-id><pub-id pub-id-type="pmid">36291761</pub-id><pub-id pub-id-type="pmcid">PMC9599678</pub-id></element-citation></ref><ref id="B13-cancers-16-01995"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benatti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gaf&#224;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barana</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scarselli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pedroni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maestri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guerzoni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roncucci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Menigatti</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Microsatellite instability and colorectal cancer prognosis</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>8332</fpage><lpage>8340</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1030</pub-id><pub-id pub-id-type="pmid">16322293</pub-id></element-citation></ref><ref id="B14-cancers-16-01995"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andr&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>De Gramont</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vernerey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chibaudel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bonnetain</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tijeras-Raballand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scriva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hickish</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tabernero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Laethem</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>4176</fpage><lpage>4187</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.63.4238</pub-id><pub-id pub-id-type="pmid">26527776</pub-id></element-citation></ref><ref id="B15-cancers-16-01995"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andr&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shiu</surname><given-names>K.-K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Punt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garcia-Carbonero</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benavides</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Pembrolizumab in Microsatellite-Instability&#8211;High Advanced Colorectal Cancer</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2207</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2017699</pub-id><pub-id pub-id-type="pmid">33264544</pub-id></element-citation></ref><ref id="B16-cancers-16-01995"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenz</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Van Cutsem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Limon</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.Y.M.</given-names></name><name name-style="western"><surname>Hendlisz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aglietta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Alfonso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Neyns</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luppi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cardin</surname><given-names>D.B.</given-names></name><etal/></person-group><article-title>First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study</article-title><source>J. Clin. Oncol.</source><year>2022</year><volume>40</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.01015</pub-id><pub-id pub-id-type="pmid">34637336</pub-id></element-citation></ref><ref id="B17-cancers-16-01995"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaissmaier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Elshiaty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Christopoulos</surname><given-names>P.</given-names></name></person-group><article-title>Breaking Bottlenecks for the TCR Therapy of Cancer</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>2095</elocation-id><pub-id pub-id-type="doi">10.3390/cells9092095</pub-id><pub-id pub-id-type="pmid">32937956</pub-id><pub-id pub-id-type="pmcid">PMC7564186</pub-id></element-citation></ref><ref id="B18-cancers-16-01995"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>Adoptive cell transfer as personalized immunotherapy for human cancer</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4967</pub-id><pub-id pub-id-type="pmid">25838374</pub-id><pub-id pub-id-type="pmcid">PMC6295668</pub-id></element-citation></ref><ref id="B19-cancers-16-01995"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name></person-group><article-title>Advances in adoptive cellular therapy for colorectal cancer: A narrative review</article-title><source>Ann. Transl. Med.</source><year>2022</year><volume>10</volume><fpage>1404</fpage><pub-id pub-id-type="doi">10.21037/atm-22-6196</pub-id><pub-id pub-id-type="pmid">36660664</pub-id><pub-id pub-id-type="pmcid">PMC9843349</pub-id></element-citation></ref><ref id="B20-cancers-16-01995"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowitz</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Bertagnolli</surname><given-names>M.M.</given-names></name></person-group><article-title>Molecular Basis of Colorectal Cancer</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>2449</fpage><lpage>2460</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0804588</pub-id><pub-id pub-id-type="pmid">20018966</pub-id><pub-id pub-id-type="pmcid">PMC2843693</pub-id></element-citation></ref><ref id="B21-cancers-16-01995"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolouzakis</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Vassilopoulou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fragkiadaki</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sapsakos</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Papadakis</surname><given-names>G.Z.</given-names></name><name name-style="western"><surname>Spandidos</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Tsatsakis</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Tsiaoussis</surname><given-names>J.</given-names></name></person-group><article-title>Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review)</article-title><source>Oncol. Rep.</source><year>2018</year><volume>39</volume><fpage>2455</fpage><lpage>2472</lpage><pub-id pub-id-type="doi">10.3892/or.2018.6330</pub-id><pub-id pub-id-type="pmid">29565457</pub-id><pub-id pub-id-type="pmcid">PMC5983921</pub-id></element-citation></ref><ref id="B22-cancers-16-01995"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pi&#241;ol-Felis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Marcelo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vi&#241;as-Salas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Valls-Bautista</surname><given-names>C.</given-names></name></person-group><article-title>Telomeres and telomerase in the clinical management of colorectal cancer</article-title><source>Clin. Transl. Oncol.</source><year>2017</year><volume>19</volume><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1007/s12094-016-1559-0</pub-id><pub-id pub-id-type="pmid">27761787</pub-id></element-citation></ref><ref id="B23-cancers-16-01995"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Marcelo</surname><given-names>T.</given-names></name><name name-style="western"><surname>S&#225;nchez-Pernaute</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pascua</surname><given-names>I.</given-names></name><name name-style="western"><surname>De Juan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Head</surname><given-names>J.</given-names></name><name name-style="western"><surname>Torres-Garc&#237;a</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Iniesta</surname><given-names>P.I.</given-names></name></person-group><article-title>Clinical Relevance of Telomere Status and Telomerase Activity in Colorectal Cancer</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0149626</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0149626</pub-id><pub-id pub-id-type="pmid">26913901</pub-id><pub-id pub-id-type="pmcid">PMC4767779</pub-id></element-citation></ref><ref id="B24-cancers-16-01995"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroupa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kubecek</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tomasova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hanak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Krupova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cervena</surname><given-names>K.</given-names></name><name name-style="western"><surname>Siskova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosendorf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hosek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vodickova</surname><given-names>L.</given-names></name><etal/></person-group><article-title>The dynamics of telomere length in primary and metastatic colorectal cancer lesions</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><fpage>9097</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-35835-9</pub-id><pub-id pub-id-type="pmid">37277368</pub-id><pub-id pub-id-type="pmcid">PMC10241861</pub-id></element-citation></ref><ref id="B25-cancers-16-01995"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>Telomere in colorectal cancer associated with distant metastases and predicted a poor prognosis</article-title><source>Transl. Cancer Res.</source><year>2021</year><volume>10</volume><fpage>2906</fpage><lpage>2917</lpage><pub-id pub-id-type="doi">10.21037/tcr-20-3341</pub-id><pub-id pub-id-type="pmid">35116600</pub-id><pub-id pub-id-type="pmcid">PMC8798752</pub-id></element-citation></ref><ref id="B26-cancers-16-01995"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsatsakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oikonomopoulou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nikolouzakis</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Vakonaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tzatzarakis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flamourakis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Renieri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fragkiadaki</surname><given-names>P.</given-names></name><name name-style="western"><surname>Iliaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bachlitzanaki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Role of telomere length in human carcinogenesis (Review)</article-title><source>Int. J. Oncol.</source><year>2023</year><volume>63</volume><fpage>78</fpage><pub-id pub-id-type="doi">10.3892/ijo.2023.5526</pub-id><pub-id pub-id-type="pmid">37232367</pub-id><pub-id pub-id-type="pmcid">PMC10552730</pub-id></element-citation></ref><ref id="B27-cancers-16-01995"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolouzakis</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Vakonaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stivaktakis</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Alegakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berdiaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Razos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Souglakos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tsatsakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsiaoussis</surname><given-names>J.</given-names></name></person-group><article-title>Novel Prognostic Biomarkers in Metastatic and Locally Advanced Colorectal Cancer: Micronuclei Frequency and Telomerase Activity in Peripheral Blood Lymphocytes</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><fpage>683605</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.683605</pub-id><pub-id pub-id-type="pmid">34262868</pub-id><pub-id pub-id-type="pmcid">PMC8274420</pub-id></element-citation></ref><ref id="B28-cancers-16-01995"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>N.P.</given-names></name></person-group><article-title>Telomeres and immune competency</article-title><source>Curr. Opin. Immunol.</source><year>2012</year><volume>24</volume><fpage>470</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2012.05.001</pub-id><pub-id pub-id-type="pmid">22626625</pub-id><pub-id pub-id-type="pmcid">PMC3423542</pub-id></element-citation></ref><ref id="B29-cancers-16-01995"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolouzakis</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Vakonaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alegakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rakitskii</surname><given-names>V.</given-names></name><name name-style="western"><surname>Svistunov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chrysos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Souglakos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tsatsakis</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Tsiaoussis</surname><given-names>J.</given-names></name></person-group><article-title>P02-06: Effect of systemic treatment on telomere length of patients with metastatic colorectal cancer</article-title><source>Toxicol. Lett.</source><year>2023</year><volume>384</volume><fpage>S83</fpage><pub-id pub-id-type="doi">10.1016/S0378-4274(23)00461-7</pub-id></element-citation></ref><ref id="B30-cancers-16-01995"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rolles</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gorgulho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tometten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roderburg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abels</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vucur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heymann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tacke</surname><given-names>F.</given-names></name><name name-style="western"><surname>Br&#252;mmendorf</surname><given-names>T.H.</given-names></name><etal/></person-group><article-title>Telomere Shortening in Peripheral Leukocytes Is Associated with Poor Survival in Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><fpage>729207</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.729207</pub-id><pub-id pub-id-type="pmid">34490122</pub-id><pub-id pub-id-type="pmcid">PMC8417059</pub-id></element-citation></ref><ref id="B31-cancers-16-01995"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levinson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gutman</surname><given-names>G.A.</given-names></name></person-group><article-title>Slipped-strand mispairing: A major mechanism for DNA sequence evolution</article-title><source>Mol. Biol. Evol.</source><year>1987</year><volume>4</volume><fpage>203</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">3328815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oxfordjournals.molbev.a040442</pub-id></element-citation></ref><ref id="B32-cancers-16-01995"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Losso</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>R.d.S.</given-names></name><name name-style="western"><surname>Gentili</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Messias-Reason</surname><given-names>I.T.</given-names></name></person-group><article-title>Microsatellite instability&#8212;MSI markers (BAT26, BAT25, D2S123, D5S346, D17S250) in rectal cancer</article-title><source>Arq. Bras. Cir. Dig.</source><year>2012</year><volume>25</volume><fpage>240</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1590/S0102-67202012000400006</pub-id><pub-id pub-id-type="pmid">23411922</pub-id></element-citation></ref><ref id="B33-cancers-16-01995"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De La Chapelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name></person-group><article-title>Clinical relevance of microsatellite instability in colorectal cancer</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>3380</fpage><lpage>3387</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.27.0652</pub-id><pub-id pub-id-type="pmid">20516444</pub-id><pub-id pub-id-type="pmcid">PMC2903331</pub-id></element-citation></ref><ref id="B34-cancers-16-01995"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>R.-Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z.-S.</given-names></name></person-group><article-title>Correlations between microsatellite instability and the biological behaviour of tumours</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2019</year><volume>145</volume><fpage>2891</fpage><lpage>2899</lpage><pub-id pub-id-type="doi">10.1007/s00432-019-03053-4</pub-id><pub-id pub-id-type="pmid">31617076</pub-id><pub-id pub-id-type="pmcid">PMC6861542</pub-id></element-citation></ref><ref id="B35-cancers-16-01995"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatalica</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Vranic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Swensen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S.</given-names></name></person-group><article-title>High microsatellite instability (MSI-H) colorectal carcinoma: A brief review of predictive biomarkers in the era of personalized medicine</article-title><source>Fam. Cancer</source><year>2016</year><volume>15</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1007/s10689-016-9884-6</pub-id><pub-id pub-id-type="pmid">26875156</pub-id><pub-id pub-id-type="pmcid">PMC4901118</pub-id></element-citation></ref><ref id="B36-cancers-16-01995"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>MLH1 Promoter Methylation Frequency in Colorectal Cancer Patients and Related Clinicopathological and Molecular Features</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e59064</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0059064</pub-id><pub-id pub-id-type="pmid">23555617</pub-id><pub-id pub-id-type="pmcid">PMC3612054</pub-id></element-citation></ref><ref id="B37-cancers-16-01995"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boland</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Terdiman</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Syngal</surname><given-names>S.</given-names></name><name name-style="western"><surname>de la Chapelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>R&#252;schoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fishel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lindor</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Burgart</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Hamelin</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability</article-title><source>J. Natl. Cancer Inst.</source><year>2004</year><volume>96</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1093/jnci/djh034</pub-id><pub-id pub-id-type="pmid">14970275</pub-id><pub-id pub-id-type="pmcid">PMC2933058</pub-id></element-citation></ref><ref id="B38-cancers-16-01995"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laghi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Malesci</surname><given-names>A.</given-names></name></person-group><article-title>Differences and evolution of the methods for the assessment of microsatellite instability</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><fpage>6313</fpage><lpage>6321</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.217</pub-id><pub-id pub-id-type="pmid">18679418</pub-id></element-citation></ref><ref id="B39-cancers-16-01995"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonneville</surname><given-names>R.</given-names></name><name name-style="western"><surname>Krook</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kautto</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Miya</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wing</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.-Z.</given-names></name><name name-style="western"><surname>Reeser</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roychowdhury</surname><given-names>S.</given-names></name></person-group><article-title>Landscape of Microsatellite Instability Across 39 Cancer Types</article-title><source>JCO Precis. Oncol.</source><year>2017</year><volume>2017</volume><fpage>PO.17.00073</fpage><pub-id pub-id-type="doi">10.1200/PO.17.00073</pub-id><pub-id pub-id-type="pmid">29850653</pub-id><pub-id pub-id-type="pmcid">PMC5972025</pub-id></element-citation></ref><ref id="B40-cancers-16-01995"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venderbosch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nagtegaal</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Maughan</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Cheadle</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Quirke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Richman</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies</article-title><source>Clin. Cancer Res.</source><year>2014</year><volume>20</volume><fpage>5322</fpage><lpage>5330</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0332</pub-id><pub-id pub-id-type="pmid">25139339</pub-id><pub-id pub-id-type="pmcid">PMC4201568</pub-id></element-citation></ref><ref id="B41-cancers-16-01995"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldstein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ensor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Vilar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Broaddus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kopetz</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)</article-title><source>Ann. Oncol.</source><year>2014</year><volume>25</volume><fpage>1032</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu100</pub-id><pub-id pub-id-type="pmid">24585723</pub-id><pub-id pub-id-type="pmcid">PMC4072907</pub-id></element-citation></ref><ref id="B42-cancers-16-01995"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer</article-title><source>JAMA Netw. Open</source><year>2022</year><volume>5</volume><fpage>e224637</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.4637</pub-id><pub-id pub-id-type="pmid">35348710</pub-id><pub-id pub-id-type="pmcid">PMC8965636</pub-id></element-citation></ref><ref id="B43-cancers-16-01995"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alemohammad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Najafzadeh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Asadzadeh</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Baghbanzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghorbaninezhad</surname><given-names>F.</given-names></name><name name-style="western"><surname>Najafzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Safarpour</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bernardini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brunetti</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sonnessa</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>146</volume><fpage>112516</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.112516</pub-id><pub-id pub-id-type="pmid">34906767</pub-id></element-citation></ref><ref id="B44-cancers-16-01995"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name></person-group><article-title>Oncology meets immunology: The cancer-immunity cycle</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id><pub-id pub-id-type="pmid">23890059</pub-id></element-citation></ref><ref id="B45-cancers-16-01995"><label>45.</label><element-citation publication-type="gov"><article-title>AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients&#8212;Full Text View&#8212;ClinicalTrials.gov</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04513951" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04513951</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-10">(accessed on 10 January 2024)</date-in-citation></element-citation></ref><ref id="B46-cancers-16-01995"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antoniotti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rossini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pietrantonio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Catteau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lonardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boquet</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tamberi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marmorino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moretto</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>876</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00274-1</pub-id><pub-id pub-id-type="pmid">35636444</pub-id></element-citation></ref><ref id="B47-cancers-16-01995"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svrcek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lascols</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Collura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jonch&#232;re</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fl&#233;jou</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Buhard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Duval</surname><given-names>A.</given-names></name></person-group><article-title>MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors</article-title><source>Bull. Cancer</source><year>2019</year><volume>106</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.bulcan.2018.12.008</pub-id><pub-id pub-id-type="pmid">30713006</pub-id></element-citation></ref><ref id="B48-cancers-16-01995"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>French</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Sargent</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Burgart</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Kabat</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>L.</given-names></name><name name-style="western"><surname>Windschitl</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Thibodeau</surname><given-names>S.N.</given-names></name></person-group><article-title>Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>3408</fpage><lpage>3415</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1489</pub-id><pub-id pub-id-type="pmid">18519771</pub-id><pub-id pub-id-type="pmcid">PMC2674786</pub-id></element-citation></ref><ref id="B49-cancers-16-01995"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toon</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Desilva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clarkson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sioson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jankova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>A.J.</given-names></name></person-group><article-title>BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer</article-title><source>Mod. Pathol.</source><year>2014</year><volume>27</volume><fpage>644</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2013.200</pub-id><pub-id pub-id-type="pmid">24157612</pub-id><pub-id pub-id-type="pmcid">PMC4021849</pub-id></element-citation></ref><ref id="B50-cancers-16-01995"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andr&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>M.E.</given-names></name></person-group><article-title>Immune Checkpoint Blockade Therapy in Patients with Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022</article-title><source>Am. Soc. Clin. Oncol. Educ. Book</source><year>2022</year><volume>42</volume><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1200/EDBK_349557</pub-id><pub-id pub-id-type="pmid">35471834</pub-id></element-citation></ref><ref id="B51-cancers-16-01995"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toon</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Capper</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clarkson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sioson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mead</surname><given-names>S.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Clendenning</surname><given-names>M.</given-names></name><etal/></person-group><article-title>BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for lynch syndrome</article-title><source>Am. J. Surg. Pathol.</source><year>2013</year><volume>37</volume><fpage>1592</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e31828f233d</pub-id><pub-id pub-id-type="pmid">23797718</pub-id><pub-id pub-id-type="pmcid">PMC3773060</pub-id></element-citation></ref><ref id="B52-cancers-16-01995"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andre</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shiu</surname><given-names>K.-K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Punt</surname><given-names>C.J.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Garcia-Carbonero</surname><given-names>R.</given-names></name><name name-style="western"><surname>Benavides</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>LBA4</fpage><pub-id pub-id-type="doi">10.1200/JCO.2020.38.18_suppl.LBA4</pub-id><pub-id pub-id-type="pmcid">PMC9533375</pub-id><pub-id pub-id-type="pmid">35427471</pub-id></element-citation></ref><ref id="B53-cancers-16-01995"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Colle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pudlarz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Heran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duval</surname><given-names>A.</given-names></name><name name-style="western"><surname>Svrcek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>T.</given-names></name></person-group><article-title>Immune checkpoint inhibition in metastatic colorectal cancer harboring microsatellite instability or mismatch repair deficiency</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>1149</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13051149</pub-id><pub-id pub-id-type="pmid">33800202</pub-id><pub-id pub-id-type="pmcid">PMC7962453</pub-id></element-citation></ref><ref id="B54-cancers-16-01995"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Lonardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lenz</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Morse</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Axelson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study</article-title><source>Lancet Oncol.</source><year>2017</year><volume>18</volume><fpage>1182</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30422-9</pub-id><pub-id pub-id-type="pmid">28734759</pub-id><pub-id pub-id-type="pmcid">PMC6207072</pub-id></element-citation></ref><ref id="B55-cancers-16-01995"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>van Cutsem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Geva</surname><given-names>R.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burge</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Neil</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kavan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yoshino</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability&#8211;high/mismatch repair&#8211;deficient metastatic colorectal cancer: KEYNOTE-164</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.02107</pub-id><pub-id pub-id-type="pmid">31725351</pub-id><pub-id pub-id-type="pmcid">PMC7031958</pub-id></element-citation></ref><ref id="B56-cancers-16-01995"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groot</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lubberts</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>R.</given-names></name><name name-style="western"><surname>Witjes</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Martijn Kerst</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Groenewegen</surname><given-names>G.</given-names></name><name name-style="western"><surname>van den Eertwegh</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Poortmans</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Kl&#252;mpen</surname><given-names>H.-J.</given-names></name><etal/></person-group><article-title>Risk of Solid Cancer after Treatment of Testicular Germ Cell Cancer in the Platinum Era</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>773</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.77.4174</pub-id><pub-id pub-id-type="pmid">29989856</pub-id></element-citation></ref><ref id="B57-cancers-16-01995"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name></person-group><article-title>Cancer immunoediting: From immunosurveillance to tumor escape</article-title><source>Nat. Immunol.</source><year>2002</year><volume>3</volume><fpage>991</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1038/ni1102-991</pub-id><pub-id pub-id-type="pmid">12407406</pub-id></element-citation></ref><ref id="B58-cancers-16-01995"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karhemo</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Hyv&#246;nen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laakkonen</surname><given-names>P.</given-names></name></person-group><article-title>Metastasis-associated cell surface oncoproteomics</article-title><source>Front. Pharmacol.</source><year>2012</year><volume>3</volume><fpage>192</fpage><pub-id pub-id-type="doi">10.3389/fphar.2012.00192</pub-id><pub-id pub-id-type="pmid">23162466</pub-id><pub-id pub-id-type="pmcid">PMC3491318</pub-id></element-citation></ref><ref id="B59-cancers-16-01995"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodman</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sokol</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Frampton</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Lippman</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy</article-title><source>Cancer Immunol. Res.</source><year>2019</year><volume>7</volume><fpage>1570</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-19-0149</pub-id><pub-id pub-id-type="pmid">31405947</pub-id><pub-id pub-id-type="pmcid">PMC6774837</pub-id></element-citation></ref><ref id="B60-cancers-16-01995"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lanier</surname><given-names>L.L.</given-names></name></person-group><article-title>Natural Killer Cells and Cancer</article-title><source>Adv. Cancer Res.</source><year>2003</year><volume>90</volume><fpage>127</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">14710949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0065-230x(03)90004-2</pub-id></element-citation></ref><ref id="B61-cancers-16-01995"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markman</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Shiao</surname><given-names>S.L.</given-names></name></person-group><article-title>Impact of the immune system and immunotherapy in colorectal cancer</article-title><source>J. Gastrointest. Oncol.</source><year>2015</year><volume>6</volume><fpage>208</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">25830040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3978/j.issn.2078-6891.2014.077</pub-id><pub-id pub-id-type="pmcid">PMC4311093</pub-id></element-citation></ref><ref id="B62-cancers-16-01995"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.W.</given-names></name></person-group><article-title>The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><fpage>868695</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.868695</pub-id><pub-id pub-id-type="pmid">35685630</pub-id><pub-id pub-id-type="pmcid">PMC9171538</pub-id></element-citation></ref><ref id="B63-cancers-16-01995"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Conejo-Garcia</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Katsaros</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gimotty</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Massobrio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Regnani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Makrigiannakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schlienger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liebman</surname><given-names>M.N.</given-names></name><etal/></person-group><article-title>Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020177</pub-id><pub-id pub-id-type="pmid">12529460</pub-id></element-citation></ref><ref id="B64-cancers-16-01995"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inagaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Komatsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yonekura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takatsuka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Utsunomiya</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: High interleukin-5 and -10 levels are significant unfavorable prognostic factors</article-title><source>Int. J. Cancer</source><year>2006</year><volume>118</volume><fpage>3054</fpage><lpage>3061</lpage><pub-id pub-id-type="doi">10.1002/ijc.21688</pub-id><pub-id pub-id-type="pmid">16425276</pub-id></element-citation></ref><ref id="B65-cancers-16-01995"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.X.</given-names></name></person-group><article-title>Tumor-infiltrating T lymphocytes: Friends or foes?</article-title><source>Lab. Investig.</source><year>2006</year><volume>86</volume><fpage>231</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3700389</pub-id><pub-id pub-id-type="pmid">16446705</pub-id></element-citation></ref><ref id="B66-cancers-16-01995"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutmuller</surname><given-names>R.P.M.</given-names></name><name name-style="western"><surname>Van Duivenvoorde</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Van Elsas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>T.N.M.</given-names></name><name name-style="western"><surname>Wildenberg</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Toes</surname><given-names>R.E.M.</given-names></name><name name-style="western"><surname>Offringa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Melief</surname><given-names>C.J.M.</given-names></name></person-group><article-title>Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses</article-title><source>J. Exp. Med.</source><year>2001</year><volume>194</volume><fpage>823</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1084/jem.194.6.823</pub-id><pub-id pub-id-type="pmid">11560997</pub-id><pub-id pub-id-type="pmcid">PMC2195955</pub-id></element-citation></ref><ref id="B67-cancers-16-01995"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schimanski</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Neurath</surname><given-names>M.F.</given-names></name></person-group><article-title>Colon cancer and the immune system: The role of tumor invading T cells</article-title><source>World J. Gastroenterol.</source><year>2006</year><volume>12</volume><fpage>7233</fpage><lpage>7238</lpage><pub-id pub-id-type="doi">10.3748/wjg.v12.i45.7233</pub-id><pub-id pub-id-type="pmid">17143936</pub-id><pub-id pub-id-type="pmcid">PMC4087478</pub-id></element-citation></ref><ref id="B68-cancers-16-01995"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guidoboni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gaf&#224;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Viel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doglioni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Santini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Del Tin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Macr&#236;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lanza</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boiocchi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis</article-title><source>Am. J. Pathol.</source><year>2001</year><volume>159</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)61695-1</pub-id><pub-id pub-id-type="pmid">11438476</pub-id><pub-id pub-id-type="pmcid">PMC1850401</pub-id></element-citation></ref><ref id="B69-cancers-16-01995"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prall</surname><given-names>F.</given-names></name><name name-style="western"><surname>D&#252;hrkop</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weirich</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ostwald</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lenz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nizze</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barten</surname><given-names>M.</given-names></name></person-group><article-title>Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability</article-title><source>Hum. Pathol.</source><year>2004</year><volume>35</volume><fpage>808</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2004.01.022</pub-id><pub-id pub-id-type="pmid">15257543</pub-id></element-citation></ref><ref id="B70-cancers-16-01995"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornista</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Giolito</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hazime</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dufait</surname><given-names>I.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khumukcham</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>De Ridder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abreu</surname><given-names>M.T.</given-names></name><etal/></person-group><article-title>Colorectal Cancer Immunotherapy: State of the Art and Future Directions</article-title><source>Gastro Hep Adv.</source><year>2023</year><volume>2</volume><fpage>1103</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1016/j.gastha.2023.09.007</pub-id><pub-id pub-id-type="pmid">38098742</pub-id><pub-id pub-id-type="pmcid">PMC10721132</pub-id></element-citation></ref><ref id="B71-cancers-16-01995"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llosa</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Cruise</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wicks</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Hechenbleikner</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Taube</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Blosser</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luber</surname><given-names>B.S.</given-names></name><etal/></person-group><article-title>The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints</article-title><source>Cancer Discov.</source><year>2015</year><volume>5</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0863</pub-id><pub-id pub-id-type="pmid">25358689</pub-id><pub-id pub-id-type="pmcid">PMC4293246</pub-id></element-citation></ref><ref id="B72-cancers-16-01995"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mezheyeuski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Micke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mart&#237;n-bernab&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Backman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hrynchyk</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hammarstr&#246;m</surname><given-names>K.</given-names></name><name name-style="western"><surname>Str&#246;m</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ekstr&#246;m</surname><given-names>J.</given-names></name><name name-style="western"><surname>Edqvist</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Sundstr&#246;m</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The immune landscape of colorectal cancer</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>5545</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13215545</pub-id><pub-id pub-id-type="pmid">34771707</pub-id><pub-id pub-id-type="pmcid">PMC8583221</pub-id></element-citation></ref><ref id="B73-cancers-16-01995"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name></person-group><article-title>The three Es of cancer immunoediting</article-title><source>Annu. Rev. Immunol.</source><year>2004</year><volume>22</volume><fpage>329</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104803</pub-id><pub-id pub-id-type="pmid">15032581</pub-id></element-citation></ref><ref id="B74-cancers-16-01995"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawaguchi</surname><given-names>T.</given-names></name></person-group><article-title>Cancer metastasis: Characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates</article-title><source>Curr. Drug Targets-Cardiovasc. Haematol. Disord.</source><year>2005</year><volume>5</volume><fpage>39</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.2174/1568006053005038</pub-id><pub-id pub-id-type="pmid">15720223</pub-id></element-citation></ref><ref id="B75-cancers-16-01995"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowling</surname><given-names>P.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Clynes</surname><given-names>M.</given-names></name></person-group><article-title>Membrane and membrane-associated proteins involved in the aggressive phenotype displayed by highly invasive cancer cells</article-title><source>Proteomics</source><year>2008</year><volume>8</volume><fpage>4054</fpage><lpage>4065</lpage><pub-id pub-id-type="doi">10.1002/pmic.200800098</pub-id><pub-id pub-id-type="pmid">18780347</pub-id></element-citation></ref><ref id="B76-cancers-16-01995"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khong</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>Natural selection of tumor variants in the generation of &#8220;tumor escape&#8221; phenotypes</article-title><source>Nat. Immunol.</source><year>2002</year><volume>3</volume><fpage>999</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1038/ni1102-999</pub-id><pub-id pub-id-type="pmid">12407407</pub-id><pub-id pub-id-type="pmcid">PMC1508168</pub-id></element-citation></ref><ref id="B77-cancers-16-01995"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Connell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>O&#8217;Sullivan</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Shanahan</surname><given-names>F.</given-names></name></person-group><article-title>The Fas counterattack: Cancer as a site of immune privilege</article-title><source>Immunol. Today</source><year>1999</year><volume>20</volume><fpage>46</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/S0167-5699(98)01382-6</pub-id><pub-id pub-id-type="pmid">10081230</pub-id></element-citation></ref><ref id="B78-cancers-16-01995"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igney</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Krammer</surname><given-names>P.H.</given-names></name></person-group><article-title>Tumor counterattack: Fact or fiction?</article-title><source>Cancer Immunol. Immunother.</source><year>2005</year><volume>54</volume><fpage>1127</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1007/s00262-005-0680-7</pub-id><pub-id pub-id-type="pmid">15889255</pub-id><pub-id pub-id-type="pmcid">PMC11034178</pub-id></element-citation></ref><ref id="B79-cancers-16-01995"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Topalian</surname><given-names>S.L.</given-names></name></person-group><article-title>The role of CD4+ T cell responses in antitumor immunity</article-title><source>Curr. Opin. Immunol.</source><year>1998</year><volume>10</volume><fpage>588</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(98)80228-8</pub-id><pub-id pub-id-type="pmid">9794842</pub-id></element-citation></ref><ref id="B80-cancers-16-01995"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabrilovich</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Girgis</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Meny</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Nadaf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kavanaugh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>D.P.</given-names></name></person-group><article-title>Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells</article-title><source>Nat. Med.</source><year>1996</year><volume>2</volume><fpage>1096</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1038/nm1096-1096</pub-id><pub-id pub-id-type="pmid">8837607</pub-id></element-citation></ref><ref id="B81-cancers-16-01995"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schroeder</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Lotan</surname><given-names>R.</given-names></name></person-group><article-title>Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib</article-title><source>Cancer Biol. Ther.</source><year>2004</year><volume>3</volume><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.4161/cbt.3.9.1037</pub-id><pub-id pub-id-type="pmid">15254428</pub-id></element-citation></ref><ref id="B82-cancers-16-01995"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Valentino</surname><given-names>J.</given-names></name><name name-style="western"><surname>Manna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Bhattacharya-Chatterjee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foon</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>O&#8217;Malley</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>S.K.</given-names></name></person-group><article-title>Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression</article-title><source>Mol. Ther.</source><year>2001</year><volume>4</volume><fpage>551</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1006/mthe.2001.0493</pub-id><pub-id pub-id-type="pmid">11735339</pub-id></element-citation></ref><ref id="B83-cancers-16-01995"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dennis</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Blatner</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Gounari</surname><given-names>F.</given-names></name><name name-style="western"><surname>Khazaie</surname><given-names>K.</given-names></name></person-group><article-title>Current status of interleukin-10 and regulatory T-cells in cancer</article-title><source>Curr. Opin. Oncol.</source><year>2013</year><volume>25</volume><fpage>637</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1097/CCO.0000000000000006</pub-id><pub-id pub-id-type="pmid">24076584</pub-id><pub-id pub-id-type="pmcid">PMC4322764</pub-id></element-citation></ref><ref id="B84-cancers-16-01995"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golshani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Advances in immunotherapy for colorectal cancer: A review</article-title><source>Therap. Adv. Gastroenterol.</source><year>2020</year><volume>13</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1177/1756284820917527</pub-id><pub-id pub-id-type="pmid">32536977</pub-id><pub-id pub-id-type="pmcid">PMC7268115</pub-id></element-citation></ref><ref id="B85-cancers-16-01995"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tumeh</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Harview</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Yearley</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Shintaku</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>E.J.M.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chmielowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Spasic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ciobanu</surname><given-names>V.</given-names></name><etal/></person-group><article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/nature13954</pub-id><pub-id pub-id-type="pmid">25428505</pub-id><pub-id pub-id-type="pmcid">PMC4246418</pub-id></element-citation></ref><ref id="B86-cancers-16-01995"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghi Rad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Monkman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Warkiani</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ladwa</surname><given-names>R.</given-names></name><name name-style="western"><surname>O&#8217;Byrne</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kulasinghe</surname><given-names>A.</given-names></name></person-group><article-title>Understanding the tumor microenvironment for effective immunotherapy</article-title><source>Med. Res. Rev.</source><year>2021</year><volume>41</volume><fpage>1474</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1002/med.21765</pub-id><pub-id pub-id-type="pmid">33277742</pub-id><pub-id pub-id-type="pmcid">PMC8247330</pub-id></element-citation></ref><ref id="B87-cancers-16-01995"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>PD-1/PD-L1 pathway: Current researches in cancer</article-title><source>Am. J. Cancer Res.</source><year>2020</year><volume>10</volume><fpage>727</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">32266087</pub-id><pub-id pub-id-type="pmcid">PMC7136921</pub-id></element-citation></ref><ref id="B88-cancers-16-01995"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Agata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shibahara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Honjo</surname><given-names>T.</given-names></name></person-group><article-title>Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death</article-title><source>EMBO J.</source><year>1992</year><volume>11</volume><fpage>3887</fpage><lpage>3895</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1992.tb05481.x</pub-id><pub-id pub-id-type="pmid">1396582</pub-id><pub-id pub-id-type="pmcid">PMC556898</pub-id></element-citation></ref><ref id="B89-cancers-16-01995"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carreno</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>M.</given-names></name></person-group><article-title>The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses</article-title><source>Annu. Rev. Immunol.</source><year>2002</year><volume>20</volume><fpage>29</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.20.091101.091806</pub-id><pub-id pub-id-type="pmid">11861596</pub-id></element-citation></ref><ref id="B90-cancers-16-01995"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Heemskerk</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wunderlich</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>White</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name></person-group><article-title>Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>1537</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-12-195792</pub-id><pub-id pub-id-type="pmid">19423728</pub-id><pub-id pub-id-type="pmcid">PMC2927090</pub-id></element-citation></ref><ref id="B91-cancers-16-01995"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staron</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Parish</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Kaech</surname><given-names>S.M.</given-names></name></person-group><article-title>The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection</article-title><source>Immunity</source><year>2014</year><volume>41</volume><fpage>802</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.10.013</pub-id><pub-id pub-id-type="pmid">25464856</pub-id><pub-id pub-id-type="pmcid">PMC4270830</pub-id></element-citation></ref><ref id="B92-cancers-16-01995"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>ADAP and SKAP 55 deficiency suppresses PD -1 expression in CD 8 + cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy</article-title><source>EMBO Mol. Med.</source><year>2015</year><volume>7</volume><fpage>754</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.15252/emmm.201404578</pub-id><pub-id pub-id-type="pmid">25851535</pub-id><pub-id pub-id-type="pmcid">PMC4459816</pub-id></element-citation></ref><ref id="B93-cancers-16-01995"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2012</year><volume>109</volume><fpage>15419</fpage><lpage>15424</lpage><pub-id pub-id-type="doi">10.1073/pnas.1206370109</pub-id><pub-id pub-id-type="pmid">22949674</pub-id><pub-id pub-id-type="pmcid">PMC3458364</pub-id></element-citation></ref><ref id="B94-cancers-16-01995"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salmaninejad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khoramshahi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Azani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soltaninejad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aslani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zamani</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Zal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nesaei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>S.M.</given-names></name></person-group><article-title>PD-1 and cancer: Molecular mechanisms and polymorphisms</article-title><source>Immunogenetics</source><year>2018</year><volume>70</volume><fpage>73</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/s00251-017-1015-5</pub-id><pub-id pub-id-type="pmid">28642997</pub-id></element-citation></ref><ref id="B95-cancers-16-01995"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanmamed</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation</article-title><source>Cancer J.</source><year>2014</year><volume>20</volume><fpage>256</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1097/PPO.0000000000000061</pub-id><pub-id pub-id-type="pmid">25098285</pub-id><pub-id pub-id-type="pmcid">PMC4455021</pub-id></element-citation></ref><ref id="B96-cancers-16-01995"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharpe</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Wherry</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>G.J.</given-names></name></person-group><article-title>The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection</article-title><source>Nat. Immunol.</source><year>2007</year><volume>8</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/ni1443</pub-id><pub-id pub-id-type="pmid">17304234</pub-id></element-citation></ref><ref id="B97-cancers-16-01995"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohaegbulam</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Assal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lazar-Molnar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zang</surname><given-names>X.</given-names></name></person-group><article-title>Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway</article-title><source>Trends Mol. Med.</source><year>2015</year><volume>21</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2014.10.009</pub-id><pub-id pub-id-type="pmid">25440090</pub-id><pub-id pub-id-type="pmcid">PMC4282825</pub-id></element-citation></ref><ref id="B98-cancers-16-01995"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abiko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsumura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hamanishi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Horikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshioka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Baba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Konishi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mandai</surname><given-names>M.</given-names></name></person-group><article-title>IFN-&#947; from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer</article-title><source>Br. J. Cancer</source><year>2015</year><volume>112</volume><fpage>1501</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1038/bjc.2015.101</pub-id><pub-id pub-id-type="pmid">25867264</pub-id><pub-id pub-id-type="pmcid">PMC4453666</pub-id></element-citation></ref><ref id="B99-cancers-16-01995"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellucci</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bommarito</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>J.</given-names></name></person-group><article-title>Interferon-&#947;-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression</article-title><source>Oncoimmunology</source><year>2015</year><volume>4</volume><fpage>e1008824</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2015.1008824</pub-id><pub-id pub-id-type="pmid">26155422</pub-id><pub-id pub-id-type="pmcid">PMC4485824</pub-id></element-citation></ref><ref id="B100-cancers-16-01995"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Diaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Saco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Escuin-Ordinas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Zaretsky</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hugo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression</article-title><source>Cell Rep.</source><year>2017</year><volume>19</volume><fpage>1189</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.04.031</pub-id><pub-id pub-id-type="pmid">28494868</pub-id><pub-id pub-id-type="pmcid">PMC6420824</pub-id></element-citation></ref><ref id="B101-cancers-16-01995"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>S.J.B.</given-names></name><name name-style="western"><surname>Watari</surname><given-names>H.</given-names></name></person-group><article-title>Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: Beyond immune evasion</article-title><source>Front. Oncol.</source><year>2018</year><volume>8</volume><fpage>386</fpage><pub-id pub-id-type="doi">10.3389/fonc.2018.00386</pub-id><pub-id pub-id-type="pmid">30283733</pub-id><pub-id pub-id-type="pmcid">PMC6156376</pub-id></element-citation></ref><ref id="B102-cancers-16-01995"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway</article-title><source>Cell Prolif.</source><year>2019</year><volume>52</volume><fpage>e12571</fpage><pub-id pub-id-type="doi">10.1111/cpr.12571</pub-id><pub-id pub-id-type="pmid">30714229</pub-id><pub-id pub-id-type="pmcid">PMC6536456</pub-id></element-citation></ref><ref id="B103-cancers-16-01995"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gowrishankar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gunatilake</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Tiffen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rizos</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hersey</surname><given-names>P.</given-names></name></person-group><article-title>Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-&#954;B</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0123410</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0123410</pub-id><pub-id pub-id-type="pmid">25844720</pub-id><pub-id pub-id-type="pmcid">PMC4386825</pub-id></element-citation></ref><ref id="B104-cancers-16-01995"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stutvoet</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Kol</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>E.G.E.</given-names></name><name name-style="western"><surname>de Bruyn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fehrmann</surname><given-names>R.S.N.</given-names></name><name name-style="western"><surname>Terwisscha van Scheltinga</surname><given-names>A.G.T.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>S.</given-names></name></person-group><article-title>MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells</article-title><source>J. Pathol.</source><year>2019</year><volume>249</volume><fpage>52</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1002/path.5280</pub-id><pub-id pub-id-type="pmid">30972766</pub-id><pub-id pub-id-type="pmcid">PMC6767771</pub-id></element-citation></ref><ref id="B105-cancers-16-01995"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okayama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mizushima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Katada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kamada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uchiyama</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines</article-title><source>Oncol. Rep.</source><year>2017</year><volume>37</volume><fpage>1545</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.3892/or.2017.5399</pub-id><pub-id pub-id-type="pmid">28112370</pub-id></element-citation></ref><ref id="B106-cancers-16-01995"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rothstein</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>C.E.</given-names></name></person-group><article-title>Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy</article-title><source>Cancer Res.</source><year>2018</year><volume>78</volume><fpage>706</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0491</pub-id><pub-id pub-id-type="pmid">29055015</pub-id></element-citation></ref><ref id="B107-cancers-16-01995"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bi</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>PD-L1 is upregulated by EBV-driven LMP1 through NF-&#954;B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma</article-title><source>J. Hematol. Oncol.</source><year>2016</year><volume>9</volume><fpage>109</fpage><pub-id pub-id-type="doi">10.1186/s13045-016-0341-7</pub-id><pub-id pub-id-type="pmid">27737703</pub-id><pub-id pub-id-type="pmcid">PMC5064887</pub-id></element-citation></ref><ref id="B108-cancers-16-01995"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Hedgehog Signaling: From Basic Biology to Cancer Therapy</article-title><source>Cell Chem. Biol.</source><year>2017</year><volume>24</volume><fpage>252</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2017.02.010</pub-id><pub-id pub-id-type="pmid">28286127</pub-id><pub-id pub-id-type="pmcid">PMC7442121</pub-id></element-citation></ref><ref id="B109-cancers-16-01995"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name></person-group><article-title>Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy</article-title><source>J. Dig. Dis.</source><year>2017</year><volume>18</volume><fpage>574</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1111/1751-2980.12538</pub-id><pub-id pub-id-type="pmid">28851046</pub-id></element-citation></ref><ref id="B110-cancers-16-01995"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Cavalcanti</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Hechtman</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Garcia-Aguilar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sadot</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ntiamoah</surname><given-names>P.</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma</article-title><source>Mod. Pathol.</source><year>2016</year><volume>29</volume><fpage>1433</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2016.139</pub-id><pub-id pub-id-type="pmid">27443512</pub-id><pub-id pub-id-type="pmcid">PMC5083129</pub-id></element-citation></ref><ref id="B111-cancers-16-01995"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scalapino</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Daikh</surname><given-names>D.I.</given-names></name></person-group><article-title>CTLA-4: A key regulatory point in the control of autoimmune disease</article-title><source>Immunol. Rev.</source><year>2008</year><volume>223</volume><fpage>143</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2008.00639.x</pub-id><pub-id pub-id-type="pmid">18613834</pub-id></element-citation></ref><ref id="B112-cancers-16-01995"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>H.</given-names></name></person-group><article-title>CTLA-4 trafficking and surface expression</article-title><source>Trends Immunol.</source><year>2008</year><volume>29</volume><fpage>272</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.it.2008.02.011</pub-id><pub-id pub-id-type="pmid">18468488</pub-id><pub-id pub-id-type="pmcid">PMC4186961</pub-id></element-citation></ref><ref id="B113-cancers-16-01995"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linsley</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Bradshaw</surname><given-names>J.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Peach</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Mittler</surname><given-names>R.S.</given-names></name></person-group><article-title>Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement</article-title><source>Immunity</source><year>1996</year><volume>4</volume><fpage>535</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80480-X</pub-id><pub-id pub-id-type="pmid">8673700</pub-id></element-citation></ref><ref id="B114-cancers-16-01995"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egen</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name></person-group><article-title>Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength</article-title><source>Immunity</source><year>2002</year><volume>16</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(01)00259-X</pub-id><pub-id pub-id-type="pmid">11825563</pub-id></element-citation></ref><ref id="B115-cancers-16-01995"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linsley</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>J.A.L.</given-names></name><name name-style="western"><surname>Brady</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bajorath</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ledbetter</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Peach</surname><given-names>R.</given-names></name></person-group><article-title>Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors</article-title><source>Immunity</source><year>1994</year><volume>1</volume><fpage>793</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(94)80021-9</pub-id><pub-id pub-id-type="pmid">7534620</pub-id></element-citation></ref><ref id="B116-cancers-16-01995"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Read</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malmstr&#246;m</surname><given-names>V.</given-names></name><name name-style="western"><surname>Powrie</surname><given-names>F.</given-names></name></person-group><article-title>Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation</article-title><source>J. Exp. Med.</source><year>2000</year><volume>192</volume><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1084/jem.192.2.295</pub-id><pub-id pub-id-type="pmid">10899916</pub-id><pub-id pub-id-type="pmcid">PMC2193261</pub-id></element-citation></ref><ref id="B117-cancers-16-01995"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>H.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bismuth</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>C.E.</given-names></name></person-group><article-title>CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization</article-title><source>Eur. J. Immunol.</source><year>2008</year><volume>38</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1002/eji.200737423</pub-id><pub-id pub-id-type="pmid">18095376</pub-id><pub-id pub-id-type="pmcid">PMC5580795</pub-id></element-citation></ref><ref id="B118-cancers-16-01995"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosseinkhani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Derakhshani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kooshkaki</surname><given-names>O.</given-names></name><name name-style="western"><surname>Shadbad</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hajiasgharzadeh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Baghbanzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Safarpour</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mokhtarzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brunetti</surname><given-names>O.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>Immune checkpoints and car-t cells: The pioneers in future cancer therapies?</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>8305</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21218305</pub-id><pub-id pub-id-type="pmid">33167514</pub-id><pub-id pub-id-type="pmcid">PMC7663909</pub-id></element-citation></ref><ref id="B119-cancers-16-01995"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peggs</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Quezada</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Korman</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name></person-group><article-title>Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies</article-title><source>J. Exp. Med.</source><year>2009</year><volume>206</volume><fpage>1717</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.1084/jem.20082492</pub-id><pub-id pub-id-type="pmid">19581407</pub-id><pub-id pub-id-type="pmcid">PMC2722174</pub-id></element-citation></ref><ref id="B120-cancers-16-01995"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selby</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Quigley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henning</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korman</surname><given-names>A.J.</given-names></name></person-group><article-title>Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells</article-title><source>Cancer Immunol. Res.</source><year>2013</year><volume>1</volume><fpage>32</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0013</pub-id><pub-id pub-id-type="pmid">24777248</pub-id></element-citation></ref><ref id="B121-cancers-16-01995"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leach</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Krummel</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name></person-group><article-title>Enhancement of antitumor immunity by CTLA-4 blockade</article-title><source>Science</source><year>1996</year><volume>271</volume><fpage>1734</fpage><lpage>1736</lpage><pub-id pub-id-type="doi">10.1126/science.271.5256.1734</pub-id><pub-id pub-id-type="pmid">8596936</pub-id></element-citation></ref><ref id="B122-cancers-16-01995"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seidel</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kabashima</surname><given-names>K.</given-names></name></person-group><article-title>Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations</article-title><source>Front. Oncol.</source><year>2018</year><volume>8</volume><fpage>86</fpage><pub-id pub-id-type="doi">10.3389/fonc.2018.00086</pub-id><pub-id pub-id-type="pmid">29644214</pub-id><pub-id pub-id-type="pmcid">PMC5883082</pub-id></element-citation></ref><ref id="B123-cancers-16-01995"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pernot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Terme</surname><given-names>M.</given-names></name><name name-style="western"><surname>Voron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Colussi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Marcheteau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tartour</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taieb</surname><given-names>J.</given-names></name></person-group><article-title>Colorectal cancer and immunity: What we know and perspectives</article-title><source>World J. Gastroenterol.</source><year>2014</year><volume>20</volume><fpage>3738</fpage><lpage>3750</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i14.3738</pub-id><pub-id pub-id-type="pmid">24833840</pub-id><pub-id pub-id-type="pmcid">PMC3983433</pub-id></element-citation></ref><ref id="B124-cancers-16-01995"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andre</surname><given-names>T.</given-names></name><name name-style="western"><surname>Amonkar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Norquist</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Shiu</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Punt</surname><given-names>C.J.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garcia-Carbonero</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): An open-label, randomised, phase 3 trial</article-title><source>Lancet Oncol.</source><year>2021</year><volume>22</volume><fpage>665</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00064-4</pub-id><pub-id pub-id-type="pmid">33812497</pub-id></element-citation></ref><ref id="B125-cancers-16-01995"><label>125.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>US National Institutes of Health</collab></person-group><source>A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy versus Regorafenib in Participants with Metastatic Colorectal Adenocarcinoma</source><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02788279">NCT02788279</ext-link></comment><publisher-name>US National Institutes of Health</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B126-cancers-16-01995"><label>126.</label><element-citation publication-type="gov"><article-title>Study Details|Atezolizumab in Patients with MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05118724" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05118724</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-13">(accessed on 13 January 2024)</date-in-citation></element-citation></ref><ref id="B127-cancers-16-01995"><label>127.</label><element-citation publication-type="gov"><article-title>Study of Induction PD-1 Blockade in Subjects with Locally Advanced Mismatch Repair Deficient Solid Tumors&#8212;Full Text View&#8212;ClinicalTrials.gov</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04165772" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04165772</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-13">(accessed on 13 January 2024)</date-in-citation></element-citation></ref><ref id="B128-cancers-16-01995"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Halk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>T.</given-names></name><name name-style="western"><surname>Blanset</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Graziano</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lonberg</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques</article-title><source>J. Immunol.</source><year>2003</year><volume>171</volume><fpage>6251</fpage><lpage>6259</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.11.6251</pub-id><pub-id pub-id-type="pmid">14634142</pub-id></element-citation></ref><ref id="B129-cancers-16-01995"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchbinder</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stephen Hodi</surname><given-names>F.</given-names></name></person-group><article-title>Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>3377</fpage><lpage>3383</lpage><pub-id pub-id-type="doi">10.1172/JCI80012</pub-id><pub-id pub-id-type="pmid">26325034</pub-id><pub-id pub-id-type="pmcid">PMC4588295</pub-id></element-citation></ref><ref id="B130-cancers-16-01995"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishikawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S.</given-names></name></person-group><article-title>Regulatory T cells in tumor immunity</article-title><source>Int. J. Cancer</source><year>2010</year><volume>127</volume><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1002/ijc.25429</pub-id><pub-id pub-id-type="pmid">20518016</pub-id></element-citation></ref><ref id="B131-cancers-16-01995"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rawat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>L.</given-names></name></person-group><article-title>Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review</article-title><source>World J. Gastrointest. Surg.</source><year>2023</year><volume>15</volume><fpage>495</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.4240/wjgs.v15.i4.495</pub-id><pub-id pub-id-type="pmid">37206081</pub-id><pub-id pub-id-type="pmcid">PMC10190721</pub-id></element-citation></ref><ref id="B132-cancers-16-01995"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leko</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name></person-group><article-title>Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors</article-title><source>Cancer Cell</source><year>2020</year><volume>38</volume><fpage>454</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.07.013</pub-id><pub-id pub-id-type="pmid">32822573</pub-id><pub-id pub-id-type="pmcid">PMC7737225</pub-id></element-citation></ref><ref id="B133-cancers-16-01995"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermannova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Caiado</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>C.F.</given-names></name></person-group><article-title>Cell Fate Reprogramming in the Era of Cancer Immunotherapy</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>714822</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.714822</pub-id><pub-id pub-id-type="pmid">34367185</pub-id><pub-id pub-id-type="pmcid">PMC8336566</pub-id></element-citation></ref><ref id="B134-cancers-16-01995"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouce</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heslop</surname><given-names>H.E.</given-names></name></person-group><article-title>Recent advances in T-cell immunotherapy for haematological malignancies</article-title><source>Br. J. Haematol.</source><year>2017</year><volume>176</volume><fpage>688</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1111/bjh.14470</pub-id><pub-id pub-id-type="pmid">27897332</pub-id><pub-id pub-id-type="pmcid">PMC5318250</pub-id></element-citation></ref><ref id="B135-cancers-16-01995"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gauthier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yakoub-Agha</surname><given-names>I.</given-names></name></person-group><article-title>Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives</article-title><source>Curr. Res. Transl. Med.</source><year>2017</year><volume>65</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.retram.2017.08.003</pub-id><pub-id pub-id-type="pmid">28988742</pub-id></element-citation></ref><ref id="B136-cancers-16-01995"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>June</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Kawalekar</surname><given-names>O.U.</given-names></name><name name-style="western"><surname>Ghassemi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milone</surname><given-names>M.C.</given-names></name></person-group><article-title>CAR T cell immunotherapy for human cancer</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>1361</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1126/science.aar6711</pub-id><pub-id pub-id-type="pmid">29567707</pub-id></element-citation></ref><ref id="B137-cancers-16-01995"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garfall</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Maus</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>W.-T.</given-names></name><name name-style="western"><surname>Lacey</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Mahnke</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Melenhorst</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Vogl</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>B.M.</given-names></name><etal/></person-group><article-title>Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>1040</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1504542</pub-id><pub-id pub-id-type="pmid">26352815</pub-id><pub-id pub-id-type="pmcid">PMC4646711</pub-id></element-citation></ref><ref id="B138-cancers-16-01995"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>McGuirk</surname><given-names>J.P.</given-names></name></person-group><article-title>CAR T cells: Continuation in a revolution of immunotherapy</article-title><source>Lancet Oncol.</source><year>2020</year><volume>21</volume><fpage>e168</fpage><lpage>e178</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30823-X</pub-id><pub-id pub-id-type="pmid">32135120</pub-id></element-citation></ref><ref id="B139-cancers-16-01995"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhaov</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y.</given-names></name></person-group><article-title>New chimeric antigen receptor design for solid tumors</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1934</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01934</pub-id><pub-id pub-id-type="pmid">29312360</pub-id><pub-id pub-id-type="pmcid">PMC5744429</pub-id></element-citation></ref><ref id="B140-cancers-16-01995"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stary</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name></person-group><article-title>Engineering chimeric antigen receptor-T cells for cancer treatment</article-title><source>Mol. Cancer</source><year>2018</year><volume>17</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s12943-018-0814-0</pub-id><pub-id pub-id-type="pmid">29448937</pub-id><pub-id pub-id-type="pmcid">PMC5815249</pub-id></element-citation></ref><ref id="B141-cancers-16-01995"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wunderlich</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Sherry</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Royal</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Topal&#237;an</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Kammula</surname><given-names>U.S.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name><etal/></person-group><article-title>Cancer regression in patients after transfer of genetically engineered lymphocytes</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>126</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1126/science.1129003</pub-id><pub-id pub-id-type="pmid">16946036</pub-id><pub-id pub-id-type="pmcid">PMC2267026</pub-id></element-citation></ref><ref id="B142-cancers-16-01995"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turcotte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gros</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hinrichs</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Wunderlich</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name></person-group><article-title>Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy</article-title><source>J. Immunol.</source><year>2013</year><volume>191</volume><fpage>2217</fpage><lpage>2225</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300538</pub-id><pub-id pub-id-type="pmid">23904171</pub-id><pub-id pub-id-type="pmcid">PMC3748336</pub-id></element-citation></ref><ref id="B143-cancers-16-01995"><label>143.</label><element-citation publication-type="gov"><article-title>Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients with Metastatic Human Papillomavirus-Associated Cancers</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT01174121" ext-link-type="uri">https://clinicaltrials.gov/study/NCT01174121</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-13">(accessed on 13 January 2024)</date-in-citation></element-citation></ref><ref id="B144-cancers-16-01995"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name></person-group><article-title>Cancer vaccines as promising immuno-therapeutics: Platforms and current progress</article-title><source>J. Hematol. Oncol.</source><year>2022</year><volume>15</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01247-x</pub-id><pub-id pub-id-type="pmid">35303904</pub-id><pub-id pub-id-type="pmcid">PMC8931585</pub-id></element-citation></ref><ref id="B145-cancers-16-01995"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name></person-group><article-title>Therapeutic cancer vaccines: Advancements, challenges, and prospects</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>450</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01674-3</pub-id><pub-id pub-id-type="pmid">38086815</pub-id><pub-id pub-id-type="pmcid">PMC10716479</pub-id></element-citation></ref><ref id="B146-cancers-16-01995"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blankenstein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Coulie</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Gilboa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>E.M.</given-names></name></person-group><article-title>The determinants of tumour immunogenicity</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1038/nrc3246</pub-id><pub-id pub-id-type="pmid">22378190</pub-id><pub-id pub-id-type="pmcid">PMC3552609</pub-id></element-citation></ref><ref id="B147-cancers-16-01995"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Oken</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>E.</given-names></name><name name-style="western"><surname>Haller</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Manola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>M.G.</given-names></name></person-group><article-title>Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283</article-title><source>J. Clin. Oncol.</source><year>2000</year><volume>18</volume><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1200/JCO.2000.18.1.148</pub-id><pub-id pub-id-type="pmid">10623705</pub-id></element-citation></ref><ref id="B148-cancers-16-01995"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jocham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Iwig</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fahlenkamp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zakrzewski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dannenberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lehmacher</surname><given-names>W.</given-names></name><name name-style="western"><surname>Von Wietersheim</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>594</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)15590-6</pub-id><pub-id pub-id-type="pmid">14987883</pub-id></element-citation></ref><ref id="B149-cancers-16-01995"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Kairys</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mastrangelo</surname><given-names>M.J.</given-names></name></person-group><article-title>Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine</article-title><source>J. Clin. Oncol.</source><year>2004</year><volume>22</volume><fpage>403</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.06.043</pub-id><pub-id pub-id-type="pmid">14691123</pub-id></element-citation></ref><ref id="B150-cancers-16-01995"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klebanoff</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Acquavella</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>Therapeutic cancer vaccines: Are we there yet?</article-title><source>Immunol. Rev.</source><year>2011</year><volume>239</volume><fpage>27</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00979.x</pub-id><pub-id pub-id-type="pmid">21198663</pub-id><pub-id pub-id-type="pmcid">PMC3075547</pub-id></element-citation></ref><ref id="B151-cancers-16-01995"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Edil</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name></person-group><article-title>Vaccine therapy for pancreatic cancer</article-title><source>Oncoimmunology</source><year>2013</year><volume>2</volume><fpage>e26662</fpage><pub-id pub-id-type="doi">10.4161/onci.26662</pub-id><pub-id pub-id-type="pmid">24498551</pub-id><pub-id pub-id-type="pmcid">PMC3912009</pub-id></element-citation></ref><ref id="B152-cancers-16-01995"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartnik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nirmal</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.-Y.</given-names></name></person-group><article-title>Peptide Vaccine Therapy in Colorectal Cancer</article-title><source>Vaccines</source><year>2013</year><volume>1</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3390/vaccines1010001</pub-id><pub-id pub-id-type="pmcid">PMC4552199</pub-id><pub-id pub-id-type="pmid">26343847</pub-id></element-citation></ref><ref id="B153-cancers-16-01995"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yankai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wentao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hongxia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jie</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rongyue</surname><given-names>C.</given-names></name><name name-style="western"><surname>Taiming</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jingjing</surname><given-names>L.</given-names></name></person-group><article-title>Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>2575</fpage><lpage>2584</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.12.030</pub-id><pub-id pub-id-type="pmid">16420967</pub-id></element-citation></ref><ref id="B154-cancers-16-01995"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bilusic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heery</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Arlen</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Rauckhorst</surname><given-names>M.</given-names></name><name name-style="western"><surname>Apelian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Jochems</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schlom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gulley</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Phase i trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma</article-title><source>Cancer Immunol. Immunother.</source><year>2014</year><volume>63</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1007/s00262-013-1505-8</pub-id><pub-id pub-id-type="pmid">24327292</pub-id><pub-id pub-id-type="pmcid">PMC3944709</pub-id></element-citation></ref><ref id="B155-cancers-16-01995"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sasada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name></person-group><article-title>Next-generation peptide vaccines for advanced cancer</article-title><source>Cancer Sci.</source><year>2013</year><volume>104</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/cas.12050</pub-id><pub-id pub-id-type="pmid">23107418</pub-id><pub-id pub-id-type="pmcid">PMC7657262</pub-id></element-citation></ref><ref id="B156-cancers-16-01995"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Speetjens</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Kuppen</surname><given-names>P.J.K.</given-names></name><name name-style="western"><surname>Welters</surname><given-names>M.J.P.</given-names></name><name name-style="western"><surname>Essahsah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Van Den Brink</surname><given-names>A.M.E.G.V.</given-names></name><name name-style="western"><surname>Lantrua</surname><given-names>M.G.K.</given-names></name><name name-style="western"><surname>Valentijn</surname><given-names>A.R.P.M.</given-names></name><name name-style="western"><surname>Oostendorp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fathers</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Nijman</surname><given-names>H.W.</given-names></name><etal/></person-group><article-title>Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer</article-title><source>Clin. Cancer Res.</source><year>2009</year><volume>15</volume><fpage>1086</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2227</pub-id><pub-id pub-id-type="pmid">19188184</pub-id></element-citation></ref><ref id="B157-cancers-16-01995"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larocca</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schlom</surname><given-names>J.</given-names></name></person-group><article-title>Viral vector-based therapeutic cancer vaccines</article-title><source>Cancer J.</source><year>2011</year><volume>17</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e3182325e63</pub-id><pub-id pub-id-type="pmid">21952287</pub-id><pub-id pub-id-type="pmcid">PMC3207353</pub-id></element-citation></ref><ref id="B158-cancers-16-01995"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gameiro</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Dreher</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Guha</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hodge</surname><given-names>J.W.</given-names></name></person-group><article-title>Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e70417</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0070417</pub-id><pub-id pub-id-type="pmid">23894654</pub-id><pub-id pub-id-type="pmcid">PMC3722166</pub-id></element-citation></ref><ref id="B159-cancers-16-01995"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulley</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Arlen</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Camphausen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mohebtash</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamrava</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schlom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Citrin</surname><given-names>D.</given-names></name></person-group><article-title>A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver</article-title><source>Expert Opin. Biol. Ther.</source><year>2011</year><volume>11</volume><fpage>1409</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1517/14712598.2011.615741</pub-id><pub-id pub-id-type="pmid">21871012</pub-id><pub-id pub-id-type="pmcid">PMC3513964</pub-id></element-citation></ref><ref id="B160-cancers-16-01995"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuyaerts</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Corthals</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neyns</surname><given-names>B.</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Breckpot</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thielemans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bonehill</surname><given-names>A.</given-names></name></person-group><article-title>Current approaches in dendritic cell generation and future implications for cancer immunotherapy</article-title><source>Cancer Immunol. Immunother.</source><year>2007</year><volume>56</volume><fpage>1513</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.1007/s00262-007-0334-z</pub-id><pub-id pub-id-type="pmid">17503040</pub-id><pub-id pub-id-type="pmcid">PMC11030932</pub-id></element-citation></ref><ref id="B161-cancers-16-01995"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wooster</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Girgis</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Brazeale</surname><given-names>H.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>D.B.</given-names></name></person-group><article-title>Dendritic cell vaccine therapy for colorectal cancer</article-title><source>Pharmacol. Res.</source><year>2021</year><volume>164</volume><fpage>105374</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.105374</pub-id><pub-id pub-id-type="pmid">33348026</pub-id><pub-id pub-id-type="pmcid">PMC7867624</pub-id></element-citation></ref><ref id="B162-cancers-16-01995"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiravand</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kashani</surname><given-names>S.M.A.</given-names></name><name name-style="western"><surname>Hosseini-Fard</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sadeghirad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ladwa</surname><given-names>R.</given-names></name><name name-style="western"><surname>O&#8217;byrne</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kulasinghe</surname><given-names>A.</given-names></name></person-group><article-title>Immune Checkpoint Inhibitors in Cancer Therapy</article-title><source>Curr. Oncol.</source><year>2022</year><volume>29</volume><fpage>3044</fpage><lpage>3060</lpage><pub-id pub-id-type="doi">10.3390/curroncol29050247</pub-id><pub-id pub-id-type="pmid">35621637</pub-id><pub-id pub-id-type="pmcid">PMC9139602</pub-id></element-citation></ref><ref id="B163-cancers-16-01995"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van den Eynde</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mlecnik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bindea</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fredriksen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Church</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Lafontaine</surname><given-names>L.</given-names></name><name name-style="western"><surname>Haicheur</surname><given-names>N.</given-names></name><name name-style="western"><surname>Marliot</surname><given-names>F.</given-names></name><name name-style="western"><surname>Angelova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vasaturo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients</article-title><source>Cancer Cell</source><year>2018</year><volume>34</volume><fpage>1012</fpage><lpage>1026.e3</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.11.003</pub-id><pub-id pub-id-type="pmid">30537506</pub-id></element-citation></ref><ref id="B164-cancers-16-01995"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>P.</given-names></name></person-group><article-title>Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>528129</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01052</pub-id><pub-id pub-id-type="pmcid">PMC7270196</pub-id><pub-id pub-id-type="pmid">32547556</pub-id></element-citation></ref><ref id="B165-cancers-16-01995"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuc&#224;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lonardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shitara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Elez</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Fakih</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klempner</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Emmett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jayachandran</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004001</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-004001</pub-id><pub-id pub-id-type="pmid">35110358</pub-id><pub-id pub-id-type="pmcid">PMC8811606</pub-id></element-citation></ref><ref id="B166-cancers-16-01995"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellucci</surname><given-names>E.</given-names></name><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Halmos</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chuy</surname><given-names>J.</given-names></name></person-group><article-title>DNA Polymerase &#949; Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity</article-title><source>Oncologist</source><year>2017</year><volume>22</volume><fpage>497</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2017-0034</pub-id><pub-id pub-id-type="pmid">28465371</pub-id><pub-id pub-id-type="pmcid">PMC5423519</pub-id></element-citation></ref><ref id="B167-cancers-16-01995"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domingo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Freeman-Mills</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Glaire</surname><given-names>M.</given-names></name><name name-style="western"><surname>Briggs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fessler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Medema</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Boot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morreau</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: A retrospective, pooled biomarker study</article-title><source>Lancet Gastroenterol. Hepatol.</source><year>2016</year><volume>1</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(16)30014-0</pub-id><pub-id pub-id-type="pmid">28404093</pub-id></element-citation></ref><ref id="B168-cancers-16-01995"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shay</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>W.E.</given-names></name></person-group><article-title>Telomeres and telomerase: Three decades of progress</article-title><source>Nat. Rev. Genet.</source><year>2019</year><volume>20</volume><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1038/s41576-019-0099-1</pub-id><pub-id pub-id-type="pmid">30760854</pub-id></element-citation></ref><ref id="B169-cancers-16-01995"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Cech</surname><given-names>T.R.</given-names></name></person-group><article-title>Shaping human telomeres: From shelterin and CST complexes to telomeric chromatin organization</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2021</year><volume>22</volume><fpage>283</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/s41580-021-00328-y</pub-id><pub-id pub-id-type="pmid">33564154</pub-id><pub-id pub-id-type="pmcid">PMC8221230</pub-id></element-citation></ref><ref id="B170-cancers-16-01995"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasilopoulos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fragkiadaki</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalliora</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fragou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Docea</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Vakonaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsoukalas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Calina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Buga</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Georgiadis</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The association of female and male infertility with telomere length (Review)</article-title><source>Int. J. Mol. Med.</source><year>2019</year><volume>44</volume><fpage>375</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2019.4225</pub-id><pub-id pub-id-type="pmid">31173155</pub-id><pub-id pub-id-type="pmcid">PMC6605974</pub-id></element-citation></ref><ref id="B171-cancers-16-01995"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Razgonova</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Zakharenko</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Golokhvast</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Thanasoula</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sarandi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nikolouzakis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fragkiadaki</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsoukalas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Spandidos</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Tsatsakis</surname><given-names>A.</given-names></name></person-group><article-title>Telomerase and telomeres in aging theory and chronographic aging theory (Review)</article-title><source>Mol. Med. Rep.</source><year>2020</year><volume>22</volume><fpage>1679</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.3892/mmr.2020.11274</pub-id><pub-id pub-id-type="pmid">32705188</pub-id><pub-id pub-id-type="pmcid">PMC7411297</pub-id></element-citation></ref><ref id="B172-cancers-16-01995"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rudolph</surname><given-names>K.L.</given-names></name></person-group><article-title>Telomere shortening and ageing</article-title><source>Z. Gerontol. Geriatr.</source><year>2007</year><volume>40</volume><fpage>314</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1007/s00391-007-0480-0</pub-id><pub-id pub-id-type="pmid">17943234</pub-id></element-citation></ref><ref id="B173-cancers-16-01995"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorgoulis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Alimonti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Bischof</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>C.</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Collado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Evangelou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ferbeyre</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Cellular Senescence: Defining a Path Forward</article-title><source>Cell</source><year>2019</year><volume>179</volume><fpage>813</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.10.005</pub-id><pub-id pub-id-type="pmid">31675495</pub-id></element-citation></ref><ref id="B174-cancers-16-01995"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossiello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jurk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Passos</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>d&#8217;Adda di Fagagna</surname><given-names>F.</given-names></name></person-group><article-title>Telomere dysfunction in ageing and age-related diseases</article-title><source>Nat. Cell Biol.</source><year>2022</year><volume>24</volume><fpage>135</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1038/s41556-022-00842-x</pub-id><pub-id pub-id-type="pmid">35165420</pub-id><pub-id pub-id-type="pmcid">PMC8985209</pub-id></element-citation></ref><ref id="B175-cancers-16-01995"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vakonaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsiminikaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Plaitis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fragkiadaki</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsoukalas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Katsikantami</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vaki</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tzatzarakis</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Spandidos</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Tsatsakis</surname><given-names>A.M.</given-names></name></person-group><article-title>Common mental disorders and association with telomere length (Review)</article-title><source>Biomed. Rep.</source><year>2018</year><volume>8</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.3892/br.2018.1040</pub-id><pub-id pub-id-type="pmid">29435268</pub-id><pub-id pub-id-type="pmcid">PMC5778888</pub-id></element-citation></ref><ref id="B176-cancers-16-01995"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maciejowski</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Lange</surname><given-names>T.</given-names></name></person-group><article-title>Telomeres in cancer: Tumour suppression and genome instability</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2017</year><volume>18</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nrm.2016.171</pub-id><pub-id pub-id-type="pmid">28096526</pub-id><pub-id pub-id-type="pmcid">PMC5589191</pub-id></element-citation></ref><ref id="B177-cancers-16-01995"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name></person-group><article-title>Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: Old actors and new players</article-title><source>Oncogene</source><year>2019</year><volume>38</volume><fpage>6172</fpage><lpage>6183</lpage><pub-id pub-id-type="doi">10.1038/s41388-019-0872-9</pub-id><pub-id pub-id-type="pmid">31285550</pub-id><pub-id pub-id-type="pmcid">PMC6756069</pub-id></element-citation></ref><ref id="B178-cancers-16-01995"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>G.</given-names></name></person-group><article-title>The association between telomere length and cancer risk in population studies</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>22243</fpage><pub-id pub-id-type="doi">10.1038/srep22243</pub-id><pub-id pub-id-type="pmid">26915412</pub-id><pub-id pub-id-type="pmcid">PMC4768100</pub-id></element-citation></ref><ref id="B179-cancers-16-01995"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jafri</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Alqahtani</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Shay</surname><given-names>J.W.</given-names></name></person-group><article-title>Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies</article-title><source>Genome Med.</source><year>2016</year><volume>8</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s13073-016-0324-x</pub-id><pub-id pub-id-type="pmid">27323951</pub-id><pub-id pub-id-type="pmcid">PMC4915101</pub-id></element-citation></ref><ref id="B180-cancers-16-01995"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Hallmarks of cancer: The next generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="B181-cancers-16-01995"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayflick</surname><given-names>L.</given-names></name></person-group><article-title>The limited in vitro lifetime of human diploid cell strains</article-title><source>Exp. Cell Res.</source><year>1965</year><volume>37</volume><fpage>614</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/0014-4827(65)90211-9</pub-id><pub-id pub-id-type="pmid">14315085</pub-id></element-citation></ref><ref id="B182-cancers-16-01995"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Coller</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.M.</given-names></name></person-group><article-title>Telomerase modulates expression of growth-controlling genes and enhances cell proliferation</article-title><source>Nat. Cell Biol.</source><year>2003</year><volume>5</volume><fpage>474</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1038/ncb985</pub-id><pub-id pub-id-type="pmid">12717449</pub-id></element-citation></ref><ref id="B183-cancers-16-01995"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saginc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Leow</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Khattar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>W.K.</given-names></name><etal/></person-group><article-title>Telomerase directly regulates NF-B-dependent transcription</article-title><source>Nat. Cell Biol.</source><year>2012</year><volume>14</volume><fpage>1270</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1038/ncb2621</pub-id><pub-id pub-id-type="pmid">23159929</pub-id></element-citation></ref><ref id="B184-cancers-16-01995"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lindvall</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bj&#246;rkholm</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>4203</fpage><lpage>4213</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.441</pub-id><pub-id pub-id-type="pmid">23045275</pub-id></element-citation></ref><ref id="B185-cancers-16-01995"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yochum</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Cleland</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>R.H.</given-names></name></person-group><article-title>A Genome-Wide Screen for &#946;-Catenin Binding Sites Identifies a Downstream Enhancer Element That Controls c -Myc Gene Expression</article-title><source>Mol. Cell. Biol.</source><year>2008</year><volume>28</volume><fpage>7368</fpage><lpage>7379</lpage><pub-id pub-id-type="doi">10.1128/MCB.00744-08</pub-id><pub-id pub-id-type="pmid">18852287</pub-id><pub-id pub-id-type="pmcid">PMC2593444</pub-id></element-citation></ref><ref id="B186-cancers-16-01995"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name></person-group><article-title>Telomere length maintenance, shortening, and lengthening</article-title><source>J. Cell. Physiol.</source><year>2014</year><volume>229</volume><fpage>1323</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1002/jcp.24537</pub-id><pub-id pub-id-type="pmid">24374808</pub-id></element-citation></ref><ref id="B187-cancers-16-01995"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palm</surname><given-names>W.</given-names></name><name name-style="western"><surname>De Lange</surname><given-names>T.</given-names></name></person-group><article-title>How shelterin protects mammalian telomeres</article-title><source>Annu. Rev. Genet.</source><year>2008</year><volume>42</volume><fpage>301</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1146/annurev.genet.41.110306.130350</pub-id><pub-id pub-id-type="pmid">18680434</pub-id></element-citation></ref><ref id="B188-cancers-16-01995"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hug</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lingner</surname><given-names>J.</given-names></name></person-group><article-title>Telomere length homeostasis</article-title><source>Chromosoma</source><year>2006</year><volume>115</volume><fpage>413</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1007/s00412-006-0067-3</pub-id><pub-id pub-id-type="pmid">16741708</pub-id></element-citation></ref><ref id="B189-cancers-16-01995"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flores</surname><given-names>I.</given-names></name><name name-style="western"><surname>Benetti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blasco</surname><given-names>M.A.</given-names></name></person-group><article-title>Telomerase regulation and stem cell behaviour</article-title><source>Curr. Opin. Cell Biol.</source><year>2006</year><volume>18</volume><fpage>254</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2006.03.003</pub-id><pub-id pub-id-type="pmid">16617011</pub-id></element-citation></ref><ref id="B190-cancers-16-01995"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name></person-group><article-title>Role of TERRA in the regulation of telomere length</article-title><source>Int. J. Biol. Sci.</source><year>2015</year><volume>11</volume><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.7150/ijbs.10528</pub-id><pub-id pub-id-type="pmid">25678850</pub-id><pub-id pub-id-type="pmcid">PMC4323371</pub-id></element-citation></ref><ref id="B191-cancers-16-01995"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azzalin</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Lingner</surname><given-names>J.</given-names></name></person-group><article-title>Telomeres: The silence is broken</article-title><source>Cell Cycle</source><year>2008</year><volume>7</volume><fpage>1161</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.4161/cc.7.9.5836</pub-id><pub-id pub-id-type="pmid">18418035</pub-id></element-citation></ref><ref id="B192-cancers-16-01995"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farnung</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Brun</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Azzalin</surname><given-names>C.M.</given-names></name></person-group><article-title>Telomerase efficiently elongates highly transcribing telomeres in human cancer cells</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e35714</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0035714</pub-id><pub-id pub-id-type="pmid">22558207</pub-id><pub-id pub-id-type="pmcid">PMC3338753</pub-id></element-citation></ref><ref id="B193-cancers-16-01995"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barthel</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez-Ledesma</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Amin</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Akdemir</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Seth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Systematic analysis of telomere length and somatic alterations in 31 cancer types</article-title><source>Nat. Genet.</source><year>2017</year><volume>49</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/ng.3781</pub-id><pub-id pub-id-type="pmid">28135248</pub-id><pub-id pub-id-type="pmcid">PMC5571729</pub-id></element-citation></ref><ref id="B194-cancers-16-01995"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroupa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rachakonda</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Liska</surname><given-names>V.</given-names></name><name name-style="western"><surname>Srinivas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Urbanova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiraskova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schneiderova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vycital</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vymetalkova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vodickova</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Relationship of telomere length in colorectal cancer patients with cancer phenotype and patient prognosis</article-title><source>Br. J. Cancer</source><year>2019</year><volume>121</volume><fpage>344</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/s41416-019-0525-3</pub-id><pub-id pub-id-type="pmid">31312029</pub-id><pub-id pub-id-type="pmcid">PMC6738117</pub-id></element-citation></ref><ref id="B195-cancers-16-01995"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Shay</surname><given-names>J.W.</given-names></name></person-group><article-title>Comparison of telomere length measurement methods</article-title><source>Philos. Trans. R. Soc. Lond. B. Biol. Sci.</source><year>2018</year><volume>373</volume><fpage>20160451</fpage><pub-id pub-id-type="doi">10.1098/rstb.2016.0451</pub-id><pub-id pub-id-type="pmid">29335378</pub-id><pub-id pub-id-type="pmcid">PMC5784071</pub-id></element-citation></ref><ref id="B196-cancers-16-01995"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaiserman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krasnienkov</surname><given-names>D.</given-names></name></person-group><article-title>Telomere Length as a Marker of Biological Age: State-of-the-Art, Open Issues, and Future Perspectives</article-title><source>Front. Genet.</source><year>2021</year><volume>11</volume><fpage>630186</fpage><pub-id pub-id-type="doi">10.3389/fgene.2020.630186</pub-id><pub-id pub-id-type="pmid">33552142</pub-id><pub-id pub-id-type="pmcid">PMC7859450</pub-id></element-citation></ref><ref id="B197-cancers-16-01995"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luu</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Adams-Haduch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miljkovic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Opresko</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.M.</given-names></name></person-group><article-title>Association between leukocyte telomere length and colorectal cancer risk in the Singapore Chinese health study</article-title><source>Clin. Transl. Gastroenterol.</source><year>2019</year><volume>10</volume><fpage>e00043</fpage><pub-id pub-id-type="doi">10.14309/ctg.0000000000000043</pub-id><pub-id pub-id-type="pmid">31117113</pub-id><pub-id pub-id-type="pmcid">PMC6602767</pub-id></element-citation></ref><ref id="B198-cancers-16-01995"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peacock</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Massey</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Vanner</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>King</surname><given-names>W.D.</given-names></name></person-group><article-title>Telomere length in the colon is related to colorectal adenoma prevalence</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><fpage>e0205697</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0205697</pub-id><pub-id pub-id-type="pmid">30332457</pub-id><pub-id pub-id-type="pmcid">PMC6192597</pub-id></element-citation></ref><ref id="B199-cancers-16-01995"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naing</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aung</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>J.W.</given-names></name></person-group><article-title>Association between telomere length and the risk of colorectal cancer: A meta-analysis of observational studies</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-016-2997-3</pub-id><pub-id pub-id-type="pmid">28056862</pub-id><pub-id pub-id-type="pmcid">PMC5216529</pub-id></element-citation></ref><ref id="B200-cancers-16-01995"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rampazzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bertorelle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Serra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Terrin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Candiotto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pucciarelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Del Bianco</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nitti</surname><given-names>D.</given-names></name><name name-style="western"><surname>De Rossi</surname><given-names>A.</given-names></name></person-group><article-title>Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers</article-title><source>Br. J. Cancer</source><year>2010</year><volume>102</volume><fpage>1300</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605644</pub-id><pub-id pub-id-type="pmid">20386541</pub-id><pub-id pub-id-type="pmcid">PMC2856015</pub-id></element-citation></ref><ref id="B201-cancers-16-01995"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Aranda</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Juan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Diaz-Lopez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sanchez-Pernaute</surname><given-names>A.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Diaz-Rubio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Balibrea</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Benito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iniesta</surname><given-names>P.</given-names></name></person-group><article-title>Correlations of telomere length, telomerase activity, and telomerlc-repeat binding factor 1 expression in colorectal carcinoma: Prognostic indications</article-title><source>Cancer</source><year>2006</year><volume>106</volume><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1002/cncr.21625</pub-id><pub-id pub-id-type="pmid">16388518</pub-id></element-citation></ref><ref id="B202-cancers-16-01995"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name></person-group><article-title>Telomerase activity as a marker for differential diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis</article-title><source>Int. J. Biol. Markers</source><year>2016</year><volume>31</volume><fpage>e126</fpage><lpage>e137</lpage><pub-id pub-id-type="doi">10.5301/jbm.5000172</pub-id><pub-id pub-id-type="pmid">26616232</pub-id></element-citation></ref><ref id="B203-cancers-16-01995"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawanishi-Tabata</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fratantonio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goldblum</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tubbs</surname><given-names>R.</given-names></name><name name-style="western"><surname>Elson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lavery</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bukowski</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Ganapathi</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Telomerase activity in stage II colorectal carcinoma: Telomerase-negative tumors are correlated with poor prognosis</article-title><source>Cancer</source><year>2002</year><volume>95</volume><fpage>1834</fpage><lpage>1839</lpage><pub-id pub-id-type="doi">10.1002/cncr.10911</pub-id><pub-id pub-id-type="pmid">12404275</pub-id></element-citation></ref><ref id="B204-cancers-16-01995"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertorelle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rampazzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pucciarelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nitti</surname><given-names>D.</given-names></name><name name-style="western"><surname>De Rossi</surname><given-names>A.</given-names></name></person-group><article-title>Telomeres, telomerase and colorectal cancer</article-title><source>World J. Gastroenterol.</source><year>2014</year><volume>20</volume><fpage>1940</fpage><lpage>1950</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i8.1940</pub-id><pub-id pub-id-type="pmid">24616570</pub-id><pub-id pub-id-type="pmcid">PMC3934464</pub-id></element-citation></ref><ref id="B205-cancers-16-01995"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cong</surname><given-names>Y.-S.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Shay</surname><given-names>J.W.</given-names></name></person-group><article-title>Human Telomerase and Its Regulation</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2002</year><volume>66</volume><fpage>407</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1128/MMBR.66.3.407-425.2002</pub-id><pub-id pub-id-type="pmid">12208997</pub-id><pub-id pub-id-type="pmcid">PMC120798</pub-id></element-citation></ref><ref id="B206-cancers-16-01995"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guilleret</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grange</surname><given-names>F.</given-names></name><name name-style="western"><surname>Braunschweig</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Benhattar</surname><given-names>J.</given-names></name></person-group><article-title>Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity</article-title><source>Int. J. Cancer</source><year>2002</year><volume>101</volume><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1002/ijc.10593</pub-id><pub-id pub-id-type="pmid">12209957</pub-id></element-citation></ref><ref id="B207-cancers-16-01995"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertorelle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Briarava</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rampazzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Biasini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Agostini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maretto</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lonardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Friso</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Mescoli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zagonel</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer</article-title><source>Br. J. Cancer</source><year>2013</year><volume>108</volume><fpage>278</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/bjc.2012.602</pub-id><pub-id pub-id-type="pmid">23322193</pub-id><pub-id pub-id-type="pmcid">PMC3566802</pub-id></element-citation></ref><ref id="B208-cancers-16-01995"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terrin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rampazzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pucciarelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Agostini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bertorelle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>G.</given-names></name><name name-style="western"><surname>DelBianco</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nitti</surname><given-names>D.</given-names></name><name name-style="western"><surname>De Rossi</surname><given-names>A.</given-names></name></person-group><article-title>Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: Implications for monitoring of neoplastic disease</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>7444</fpage><lpage>7451</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0478</pub-id><pub-id pub-id-type="pmid">19010861</pub-id></element-citation></ref><ref id="B209-cancers-16-01995"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rampazzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Del Bianco</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bertorelle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spiro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bergamo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Belluco</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buonadonna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Palazzari</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients</article-title><source>Br. J. Cancer</source><year>2018</year><volume>118</volume><fpage>878</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.492</pub-id><pub-id pub-id-type="pmid">29449673</pub-id><pub-id pub-id-type="pmcid">PMC5877438</pub-id></element-citation></ref><ref id="B210-cancers-16-01995"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laish</surname><given-names>I.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Mahajna</surname><given-names>H.</given-names></name><name name-style="western"><surname>Albshesh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Horesh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shinar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Picard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Yavzori</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><fpage>962473</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.962473</pub-id><pub-id pub-id-type="pmid">36203446</pub-id><pub-id pub-id-type="pmcid">PMC9530579</pub-id></element-citation></ref><ref id="B211-cancers-16-01995"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dom&#237;nguez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Citores</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Collado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonilla</surname><given-names>F.</given-names></name></person-group><article-title>Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched</article-title><source>RNA</source><year>2008</year><volume>14</volume><fpage>1424</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1261/rna.755908</pub-id><pub-id pub-id-type="pmid">18456845</pub-id><pub-id pub-id-type="pmcid">PMC2441977</pub-id></element-citation></ref><ref id="B212-cancers-16-01995"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gabrani</surname><given-names>R.</given-names></name></person-group><article-title>Recent Patents on Anti-Telomerase Cancer Therapy</article-title><source>Recent Pat. Anticancer. Drug Discov.</source><year>2011</year><volume>7</volume><fpage>102</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.2174/157489212798357958</pub-id><pub-id pub-id-type="pmid">21854360</pub-id></element-citation></ref><ref id="B213-cancers-16-01995"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stohr</surname><given-names>B.A.</given-names></name></person-group><article-title>The role of telomere biology in cancer</article-title><source>Annu. Rev. Pathol. Mech. Dis.</source><year>2013</year><volume>8</volume><fpage>49</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-020712-164030</pub-id><pub-id pub-id-type="pmid">22934675</pub-id></element-citation></ref><ref id="B214-cancers-16-01995"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors</article-title><source>Cytotherapy</source><year>2023</year><volume>25</volume><fpage>1236</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2023.07.006</pub-id><pub-id pub-id-type="pmid">37632518</pub-id></element-citation></ref><ref id="B215-cancers-16-01995"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorissen</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pouliot</surname><given-names>N.</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>T.P.J.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>A.W.</given-names></name></person-group><article-title>Epidermal growth factor receptor: Mechanisms of activation and signalling</article-title><source>Exp. Cell Res.</source><year>2003</year><volume>284</volume><fpage>31</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/S0014-4827(02)00098-8</pub-id><pub-id pub-id-type="pmid">12648464</pub-id></element-citation></ref><ref id="B216-cancers-16-01995"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>J.C.S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>To</surname><given-names>S.S.T.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>H.K.</given-names></name></person-group><article-title>Antisense epidermal growth factor receptor RNA transfection in human glioblastoma cells down-regulates telomerase activity and telomere length</article-title><source>Br. J. Cancer</source><year>2002</year><volume>86</volume><fpage>1328</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600244</pub-id><pub-id pub-id-type="pmid">11953893</pub-id><pub-id pub-id-type="pmcid">PMC2375350</pub-id></element-citation></ref><ref id="B217-cancers-16-01995"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunimura</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shimizi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yasumoto</surname><given-names>S.</given-names></name></person-group><article-title>Telomerase activity in a specific cell subset co-expressing integrin &#946;1/EGFR but not p75(NGFR)/bcl2/integrin &#946;4 in normal human epithelial cells</article-title><source>Oncogene</source><year>1998</year><volume>17</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201916</pub-id><pub-id pub-id-type="pmid">9674703</pub-id></element-citation></ref><ref id="B218-cancers-16-01995"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heeg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hirt</surname><given-names>N.</given-names></name><name name-style="western"><surname>Queisser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schmieg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thaler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kunert</surname><given-names>H.</given-names></name><name name-style="western"><surname>Quante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goessel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Von Werder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harder</surname><given-names>J.</given-names></name><etal/></person-group><article-title>EGFR overexpression induces activation of telomerase via PI3K/AKT-mediated phosphorylation and transcriptional regulation through Hif1-alpha in a cellular model of oral-esophageal carcinogenesis</article-title><source>Cancer Sci.</source><year>2011</year><volume>102</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01796.x</pub-id><pub-id pub-id-type="pmid">21156006</pub-id></element-citation></ref><ref id="B219-cancers-16-01995"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douillard</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Oliner</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Siena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tabernero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burkes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barugel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Humblet</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bodoky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jassem</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Panitumumab&#8211;FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>369</volume><fpage>1023</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1305275</pub-id><pub-id pub-id-type="pmid">24024839</pub-id></element-citation></ref><ref id="B220-cancers-16-01995"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Augustine</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Baig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Budagov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Atzmon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mariadason</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Aparo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maitra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goel</surname><given-names>S.</given-names></name></person-group><article-title>Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer</article-title><source>Br. J. Cancer</source><year>2015</year><volume>112</volume><fpage>313</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1038/bjc.2014.561</pub-id><pub-id pub-id-type="pmid">25412235</pub-id><pub-id pub-id-type="pmcid">PMC4453445</pub-id></element-citation></ref><ref id="B221-cancers-16-01995"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jurk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Passos</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Oakley</surname><given-names>F.</given-names></name><name name-style="western"><surname>Correia-Melo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Greaves</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saretzki</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lawless</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Chronic inflammation induces telomere dysfunction and accelerates ageing in mice</article-title><source>Nat. Commun.</source><year>2014</year><volume>2</volume><fpage>4172</fpage><pub-id pub-id-type="doi">10.1038/ncomms5172</pub-id><pub-id pub-id-type="pmid">24960204</pub-id><pub-id pub-id-type="pmcid">PMC4090717</pub-id></element-citation></ref><ref id="B222-cancers-16-01995"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puterman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>E.</given-names></name><name name-style="western"><surname>O&#8217;Donovan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>N.</given-names></name><name name-style="western"><surname>Epel</surname><given-names>E.</given-names></name></person-group><article-title>The power of exercise: Buffering the effect of chronic stress on telomere length</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e10837</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0010837</pub-id><pub-id pub-id-type="pmid">20520771</pub-id><pub-id pub-id-type="pmcid">PMC2877102</pub-id></element-citation></ref><ref id="B223-cancers-16-01995"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Immunosenescence: A key player in cancer development</article-title><source>J. Hematol. Oncol.</source><year>2020</year><volume>13</volume><fpage>151</fpage><pub-id pub-id-type="doi">10.1186/s13045-020-00986-z</pub-id><pub-id pub-id-type="pmid">33168037</pub-id><pub-id pub-id-type="pmcid">PMC7653700</pub-id></element-citation></ref><ref id="B224-cancers-16-01995"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rufer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Br&#252;mmendorf</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Kolvraa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>C.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wadsworth</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schulzer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lansdorp</surname><given-names>P.M.</given-names></name></person-group><article-title>Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood</article-title><source>J. Exp. Med.</source><year>1999</year><volume>190</volume><fpage>157</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1084/jem.190.2.157</pub-id><pub-id pub-id-type="pmid">10432279</pub-id><pub-id pub-id-type="pmcid">PMC2195579</pub-id></element-citation></ref><ref id="B225-cancers-16-01995"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Effros</surname><given-names>R.B.</given-names></name></person-group><article-title>Replicative senescence of CD8 T cells: Effect on human ageing</article-title><source>Exp. Gerontol.</source><year>2004</year><volume>39</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2003.09.024</pub-id><pub-id pub-id-type="pmid">15050285</pub-id></element-citation></ref><ref id="B226-cancers-16-01995"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mengesha</surname><given-names>E.</given-names></name><name name-style="western"><surname>Albano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stephen Nichols</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klinenberg</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Linker-Israeli</surname><given-names>M.</given-names></name></person-group><article-title>Telomere shortening and decreased replicative potential, contrasted by continued proliferation of telomerase-positive CD8+CD2810 T cells in patients with systemic lupus erythematosus</article-title><source>Clin. Immunol. Immunopathol.</source><year>2001</year><volume>99</volume><fpage>211</fpage><lpage>221</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/clim.2001.5023</pub-id><pub-id pub-id-type="pmid">11318593</pub-id></element-citation></ref><ref id="B227-cancers-16-01995"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Son</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yanovski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hodes</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>N.</given-names></name></person-group><article-title>Lineage-Specific Telomere Shortening and Unaltered Capacity for Telomerase Expression in Human T and B Lymphocytes with Age</article-title><source>J. Immunol.</source><year>2000</year><volume>165</volume><fpage>1191</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.3.1191</pub-id><pub-id pub-id-type="pmid">10903716</pub-id></element-citation></ref><ref id="B228-cancers-16-01995"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Berg</surname><given-names>P.J.E.J.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>S.-L.</given-names></name><name name-style="western"><surname>Macaulay</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bemelman</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Henson</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>ten Berge</surname><given-names>I.J.M.</given-names></name><name name-style="western"><surname>Akbar</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>van Lier</surname><given-names>R.A.W.</given-names></name></person-group><article-title>Cytomegalovirus Infection Reduces Telomere Length of the Circulating T Cell Pool</article-title><source>J. Immunol.</source><year>2010</year><volume>184</volume><fpage>3417</fpage><lpage>3423</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903442</pub-id><pub-id pub-id-type="pmid">20176738</pub-id></element-citation></ref><ref id="B229-cancers-16-01995"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name></person-group><article-title>The future of immune checkpoint therapy</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1126/science.aaa8172</pub-id><pub-id pub-id-type="pmid">25838373</pub-id></element-citation></ref><ref id="B230-cancers-16-01995"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latchman</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Chernova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>D.</given-names></name><name name-style="western"><surname>Borde</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chernova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Iwai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Long</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>R.</given-names></name><etal/></person-group><article-title>PD-L2 is a second ligand for PD-1 and inhibits T cell activation</article-title><source>Nat. Immunol.</source><year>2001</year><volume>2</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1038/85330</pub-id><pub-id pub-id-type="pmid">11224527</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="cancers-16-01995-f001" orientation="portrait"><label>Figure 1</label><caption><p>A graphical presentation of T cells infiltrating a tumor site in MSI-H CRC as a result of the increased mutational burden induced by the deficient mismatch repair system.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cancers-16-01995-g001.jpg"/></fig><fig position="float" id="cancers-16-01995-f002" orientation="portrait"><label>Figure 2</label><caption><p>Graphical presentation of T-cell activation through the PD1/CTLA-4 pathway. Dendritic cells are able to activate T cells through the cross talk of the transmembrane proteins MHC II and TCR/CD4. However, this activating interaction can be canceled downstream if PD-L1/2 and CD80/86 expressed on the surface of dendritic cells connect with PD-1 and CTLA-4, respectively. This deactivating action can be counteracted through the inhibition of anti-PD-1/antiCTLA-4 antibodies. This allows activated T cells to enter the tumor microenvironment and eliminate cancer cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cancers-16-01995-g002.jpg"/></fig><table-wrap position="float" id="cancers-16-01995-t001" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01995-t001_Table 1</object-id><label>Table 1</label><caption><p>Presentation of the different categories and types of therapeutic applications for colorectal cancer. Immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), chimeric antigen receptor (CAR) T-cell, tumor-infiltrating lymphocyte (TIL).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Colorectal Cancer Immunotherapy</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Category</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">ICIs</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACT</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-Tumor Vaccines</th></tr></thead><tbody><tr><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Type</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Anti PDL1Abs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atezolimumab</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">CAR-T</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Whole tumor</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avelumab</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Durvalumab</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Anti PD-1 Abs</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab</td><td rowspan="5" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">TILs</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Peptide antigen</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cemiplimab</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Anti-CTLA-4 Abs</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Ipilimumab</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral vector</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendritic cells</td></tr></tbody></table></table-wrap><table-wrap position="float" id="cancers-16-01995-t002" orientation="portrait"><object-id pub-id-type="pii">cancers-16-01995-t002_Table 2</object-id><label>Table 2</label><caption><p>Presentation of the main categories of immune-mediated anti-tumor vaccine platforms along with their advantages and disadvantages.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Anti-Tumor Vaccines</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advantages</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disadvantages</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Conclusion</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Whole tumor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer tissue (Autologous)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patient-specific</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross reaction with normal cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant benefits in OS/DFS</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide antigen</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor-specific peptides (Heterologous)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Less cross reactions with normal cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Low immunogenicity</p></list-item><list-item><p>HLA specific</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive results</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral vector</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombined Tumor-specific peptides (Heterologous) with viral/bacterial vectors</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Less cross reactions with normal cells</p></list-item><list-item><p>Increased immunogenicity</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive results</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendritic cells</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendritic cells (Autologous)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High specificity</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time-consuming</p></list-item><list-item><p>Expensive</p></list-item><list-item><p>Low availability</p></list-item></list>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed results</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>